{"aaData": [["67000", "LIP, EXTERNAL UPPER", "
\nPrimary Tumor (T)\nT4 Tumor invades adjacent structures (e.g.,\n (lip) through cortical bone, inferior alveolar\n nerve, floor of mouth, skin of face)\n (oral cavity) through cortical bone, into deep [extrinsic]\n muscle of tongue, maxillary sinus, skin.\n Superficial erosion alone of bone/tooth\n socket by gingival primary is not sufficient\n to classify as T4)\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor 2 cm or less in greatest dimension\nT2 Tumor more than 2 cm but not more than 4\n cm in greatest dimension\nT3 Tumor more than 4 cm in greatest dimension\n\n
\nRegional Lymph Nodes (N)\n greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes,\n none more than 6 cm in greatest dimension\nN2c Metastasis in bilateral or contralateral lymph\n nodes, none more than 6 cm in greatest dimension\nN3 Metastasis in a lymph node more than 6 cm in\n greatest dimension\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node,\n 3 cm or less in greatest dimension\nN2 Choose from N2a, N2b or N2c\nN2a Metastasis in a single ipsilateral lymph node\n more than 3 cm but not more than 6 cm in\n\n
\nPrimary Tumor (T)\nT4a (lip) Tumor invades through cortical bone, inferior\n alveolar nerve, floor of mouth, or skin of face,\n i.e. chin or nose\nT4a (oral cavity) Tumor invades adjacent structures\n (e.g. through cortical bone, into deep [extrin-\n sic] muscle of the tongue [genioglossus, hyoglos-\n sus, palatoglossus, and styloglossus], maxillary\n sinus, skin of face)\nT4b Tumor invades masticator space, pterygoid\n plates, or skull base and/or encases internal ca-\n\n rotid artery\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor 2 cm or less in greatest dimension\nT2 Tumor more than 2 cm but not more than 4\n cm in greatest dimension\nT3 Tumor more than 4 cm in greatest dimension\n\n
\nRegional Lymph Nodes (N)\n dimension\nN2b Metastasis in multiple ipsilateral lymph nodes,\n none more than 6 cm in greatest dimension\nN2c Metastasis in bilateral or contralateral lymph\n nodes, none more than 6 cm in greatest dimension\nN3 Metastasis in a lymph node more than 6 cm in\n greatest dimension\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node, 3 cm\n or less in greatest dimension\nN2 Choose from N2a, N2b or N2c\nN2a Metastasis in a single ipsilateral lymph node more\n than 3 cm but not more than 6 cm in greatest\n\n
\nPrimary Tumor (T)\n (lip) Tumor invades through cortical bone, inferior alveolar nerve,\n floor of mouth, or skin of face, i.e., chin or nose\n (oral cavity) Tumor invades adjacent structures only (e.g., through\n cortical bone, [mandible or maxilla] into deep [extrinsic] muscle\n of tongue [genioglossus, hyoglossus, palatoglossus, and\n styloglossus], maxillary sinus, skin of face)\nT4b Very advanced local disease.\n Tumor invades masticator space, pterygoid plates, or skull base\n and/or encases internal carotid artery\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ\nT1 Tumor 2 cm or less in greatest dimension\nT2 Tumor more than 2 cm but not more than 4 cm in greatest dimension\nT3 Tumor more than 4 cm in greatest dimension\nT4a Moderately advanced local disease.\n\n
\nRegional Lymph Nodes (N)\n bilateral or contralateral lymph nodes, none more than 6 cm in\n greatest dimension\nN2a Metastasis in single ipsilateral lymph node more than 3 cm but not\n more than 6 cm in greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm\n in greatest dimension\nN2c Metastasis in bilateral or contralateral lymph nodes, none more than\n 6 cm in greatest dimension\nN3 Metastasis in a lymph node more than 6 cm in greatest dimension\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node, 3 cm or less in\n greatest dimension\nN2 Metastasis in a single ipsilateral lymph node, more than 3 cm but not\n more than 6 cm in greatest dimension; or in multiple ipsilateral\n lymph nodes, none more than 6 cm in greatest dimension; or in\n\n
\nPrimary Tumor (T)\nT3 Tumor having extraparenchymal extension without\n seventh nerve involvement and/or more than 4 cm\n but not more than 6 cm in greatest dimension\nT4 Tumor invades base of skull, seventh nerve,\n and/or exceeds 6 cm in greatest dimension\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor 2 cm or less in greatest dimension\n without extraparenchymal extension\nT2 Tumor more than 2 cm but not more than 4 cm\n in greatest dimension without extraparenchymal\n extension\n\n
\nRegional Lymph Nodes (N)\n greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes,\n none more than 6 cm in greatest dimension\nN2c Metastasis in bilateral or contralateral lymph\n nodes, none more than 6 cm in greatest dimension\nN3 Metastasis in a lymph node more than 6 cm in\n greatest dimension\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node,\n 3 cm or less in greatest dimension\nN2 Choose from N2a, N2b or N2c\nN2a Metastasis in a single ipsilateral lymph node\n more than 3 cm but not more than 6 cm in\n\n
\nPrimary Tumor (T)\nT3 Tumor more than 4 cm and/or tumor having\n extraparenchymal extension\nT4a Tumor invades skin, mandible, ear canal,\n and/or facial nerve\nT4b Tumor invades skull base and/or pterygoid\n plates and/or encases carotid artery\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor 2 cm or less in greatest dimension\n without extraparenchymal extension\nT2 Tumor more than 2 cm but not more than 4 cm\n in greatest dimension without extraparenchymal\n extension\n\n
\nPrimary Tumor (T)\n extension\nT4a Moderately advanced disease\n Tumor invades skin, mandible, ear canal, and/or facial nerve\nT4b Very advanced disease\n Tumor invades skull base and/or pterygoid plates and/or encases\n carotid artery\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor 2 cm or less in greatest dimension without extraparenchymal\n extension\nT2 Tumor more than 2 cm but not more than 4 cm in greatest dimension\n without extraparenchymal extension\nT3 Tumor more than 4 cm and/or tumor having extraparenchymal\n\n
\nRegional Lymph Nodes (N)\n bilateral or contralateral lymph nodes, none more than 6 cm in\n greatest dimension\nN2a Metastasis in a single ipsilateral lymph node, more than 3 cm but not\n more than 6 cm in greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm\n in greatest dimension\nN2c Metastasis in bilateral or contralateral lymph nodes, none more than\n 6 cm in greatest dimension\nN3 Metastasis in a lymph node, more than 6 cm in greatest dimension\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node, 3 cm or less in\n greatest dimension\nN2 Metastasis in a single ipsilateral lymph node, more than 3 cm but not\n more than 6 cm in greatest dimension, or in multiple ipsilateral\n lymph nodes, none more than 6 cm in greatest dimension, or in\n\n
\nPrimary Tumor (T)\nT4 Tumor invades adjacent structures (e.g.,\n pterygoid muscle(s), mandible, hard palate,\n deep muscle of tongue, larynx)\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor 2 cm or less in greatest dimension\nT2 Tumor more than 2 cm but not more than\n 4 cm in greatest dimension\nT3 Tumor more than 4 cm in greatest dimension\n\n
\nRegional Lymph Nodes (N)\n greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes,\n none more than 6 cm in greatest dimension\nN2c Metastasis in bilateral or contralateral lymph\n nodes, none more than 6 cm in greatest dimension\nN3 Metastasis in a lymph node more than 6 cm in\n greatest dimension\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node,\n 3 cm or less in greatest dimension\nN2 Choose from N2a, N2b or N2c\nN2a Metastasis in a single ipsilateral lymph node\n more than 3 cm but not more than 6 cm in\n\n
\nPrimary Tumor (T)\nT4a Tumor invades the larynx, deep/extrinsic\n muscle of tongue, medial pterygoid hard palate, or\n mandible\nT4b Tumor invades the lateral pterygoid muscle,\n pterygoid plates, lateral nasopharynx, or skull\n base or encases carotid artery\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor 2 cm or less in greatest dimension\nT2 Tumor more than 2 cm but not more than\n 4 cm in greatest dimension\nT3 Tumor more than 4 cm in greatest dimension\n\n
\nRegional Lymph Nodes (N)\n greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes,\n none more than 6 cm in greatest dimension\nN2c Metastasis in bilateral or contralateral lymph\n nodes, none more than 6 cm in greatest dimension\nN3 Metastasis in a lymph node more than 6 cm in\n greatest dimension\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node,\n 3 cm or less in greatest dimension\nN2 Choose from N2a, N2b or N2c\nN2a Metastasis in a single ipsilateral lymph node\n more than 3 cm but not more than 6 cm in\n\n
\nPrimary Tumor (T)\nT4a Moderately advanced local disease.\n Tumor invades the larynx, extrinsic muscle of tongue, medial\n pterygoid, hard palate, or mandible\nT4b Very advanced local disease.\n Tumor invades lateral pterygoid muscle, pterygoid plates, lateral \n nasopharynx, or skull base or encases carotid artery\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ\nT1 Tumor 2 cm or less in greatest dimension\nT2 Tumor more than 2 cm but not more than 4 cm in greatest dimension\nT3 Tumor more than 4 cm in greatest dimension or extension to lingual \n surface of epiglottis\n\n
\nRegional Lymph Nodes (N)\n bilateral or contralateral lymph nodes, none more than 6 cm in\n greatest dimension\nN2a Metastasis in a single ipsilateral lymph node more than 3 cm but not\n more than 6 cm in greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm\n in greatest dimension\nN2c Metastasis in bilateral or contralateral lymph nodes, none more than\n 6 cm in greatest dimension\nN3 Metastasis in a lymph node more than 6 cm in greatest dimension\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node, 3 cm or less in\n greatest dimension\nN2 Metastasis in a single ipsilateral lymph node, more than 3 cm but not\n more than 6 cm in greatest dimension, or in multiple ipsilateral\n lymph nodes, none more than 6 cm in greatest dimension, or in\n\n
\nPrimary Tumor (T)\nT2b with parapharyngeal extension\nT3 Tumor invades bony structures and/or\n paranasal sinuses\nT4 Tumor with intracranial extension and/or\n involvement of cranial nerves, infratemporal\n fossa, hypopharynx, or orbit, or masticator\n space\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor confined to the nasopharynx\nT2 Tumor extends to soft tissues of\n oropharynx and/or nasal fossa\nT2a without parapharyngeal extension\n\n
\nRegional Lymph Nodes (N)\n above the supraclavicular fossa\nN3 Metastasis in a lymph node(s)\n N3a greater than 6 cm in dimension\n N3b extension to the supraclavicular fossa\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Unilateral metastasis in lymph node(s),\n 6 cm or less in greatest dimension,\n above the supraclavicular fossa\nN2 Bilateral metastasis in lymph node(s),\n 6 cm or less in greatest dimension,\n\n
\nPrimary Tumor (T)\nT4 Tumor with intracranial extension and/or involvement of involvement\n of cranial nerves, hypopharynx, orbit, or with extension to the\n infratemporal fossa/ masticator space\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ\nT1 Tumor confined to the nasopharynx, or extends to oropharynx and/or\n nasal cavity without parapharyngeal extension\nT2 Tumor with parapharyngeal extension\nT3 Tumor involves bony structures of skull base and/or paranasal sinuses\n\n
\nRegional Lymph Nodes (N)\n dimension, above the supraclavicular fossa\nN3 Metastasis in a lymph node(s)* >6 cm and/or extension to\n supraclavicular fossa\nN3a Greater than 6 cm in dimension\nN3b Extension to the supraclavicular fossa\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Unilateral metastasis in lymph node(s), 6 cm or less in greatest \n dimension, above the supraclavicular fossa, and/or unilateral or\n bilateral, retropharyngeal lymph nodes, 6 cm or less, in greatest\n dimension\nN2 Bilateral metastasis in lymph node(s), 6 cm or less in greatest \n\n
\nSchema Discriminator\n \n010 Posterior wall of nasopharynx \n Posterior wall of nasopharynx NOS \n020 Adenoid\n Pharyngeal tonsil\n Nasopharyngeal tonsil \n100 OBSOLETE DATA RETAINED V0200\n C11.1 - originally coded in CSv1 \n\n
\nPrimary Tumor (T)\n than 2 cm but not more than 4 cm in greatest\n dimension without fixation of hemilarynx\nT3 Tumor measures more than 4 cm in greatest dimension\n or with fixation of hemilarynx\nT4 Tumor invades adjacent structures (e.g.,\n thyroid/cricoid cartilage, carotid artery,\n soft tissues of neck, prevertebral fascia/\n muscles, thyroid and/or esophagus\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor limited to one subsite of hypopharynx\n and 2 cm or less in greatest dimension\nT2 Tumor involves more than one subsite of\n hypopharynx or an adjacent site, or measures more\n\n
\nRegional Lymph Nodes (N)\n greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes,\n none more than 6 cm in greatest dimension\nN2c Metastasis in bilateral or contralateral lymph\n nodes, none more than 6 cm in greatest dimension\nN3 Metastasis in a lymph node more than 6 cm in\n greatest dimension\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node,\n 3 cm or less in greatest dimension\nN2 Choose from N2a, N2b or N2c\nN2a Metastasis in a single ipsilateral lymph node\n more than 3 cm but not more than 6 cm in\n\n
\nPrimary Tumor (T)\n than 2 cm but not more than 4 cm in greatest\n dimension without fixation of hemilarynx\nT3 Tumor measures more than 4 cm in greatest dimension\n or with fixation of hemilarynx\nT4a Tumor invades thyroid/cricoid cartilage,\n hyoid bone, thyroid gland, esophagus, or central\n compartment soft tissue (which includes pre-\n laryngeal strap muscles and subcutaneous fat)\nT4b Tumor invades prevertebral fascia, encases\n carotid artery, or involves mediastinal structures\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor limited to one subsite of hypopharynx\n and 2 cm or less in greatest dimension\nT2 Tumor involves more than one subsite of\n hypopharynx or an adjacent site, or measures more\n\n
\nPrimary Tumor (T)\n dimension without fixation of hemilarynx\nT3 Tumor more than 4 cm in greatest dimension or with fixation of\n hemilarynx or extension to esophagus\nT4a Moderately advanced local disease.\n Tumor invades thyroid/cricoid cartilage, hyoid bone, thyroid gland,\n or central compartment soft tissue\nT4b Very advanced local disease.\n Tumor invades prevertebral fascia, encases carotid artery, or\n involves mediastinal structures\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ\nT1 Tumor limited to one subsite of hypopharynx and/or 2 cm or less in \n greatest dimension\nT2 Tumor invades more than one subsite of hypopharynx or an adjacent\n site, or measures more than 2 cm but not more than 4 cm in greatest\n\n
\nRegional Lymph Nodes (N)\n bilateral or contralateral lymph nodes, none more than 6 cm in\n greatest dimension\nN2a Metastasis in a single ipsilateral lymph node more than 3 cm but not\n more than 6 cm in greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm\n in greatest dimension\nN2c Metastasis in bilateral or contralateral lymph nodes, none more than\n 6 cm in greatest dimension\nN3 Metastasis in a lymph node more than 6 cm in greatest dimension\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node, 3 cm or less in\n greatest dimension\nN2 Metastasis in a single ipsilateral lymph node, more than 3 cm but not\n more than 6 cm in greatest dimension, or in multiple ipsilateral\n lymph nodes, none more than 6 cm in greatest dimension, or in\n\n
\nPrimary Tumor (T)\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor invades lamina propria or submucosa\nT2 Tumor invades muscularis propria\nT3 Tumor invades adventitia\nT4 Tumor invades adjacent structures\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\nT3 Tumor invades adventitia\nT4 Tumor invades adjacent structures\nT4a Resectable tumor invading pleura, pericardium, or diaphragm\nT4b Unresectable tumor invading other adjacent structures, such as aorta,\n vertebral body, trachea, etc.\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis High-grade dysplasia\nT1 Tumor invades lamina propria, muscularis mucosae, or submucosa\nT1a Tumor invades lamina propria or muscularis mucosae\nT1b Tumor invades submucosa\nT2 Tumor invades muscularis propria\n\n
\nRegional Lymph Nodes (N)\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastases involving 1 to 2 nodes\nN2 Regional lymph node metastases involving 3 to 6 nodes\nN3 Regional lymph node metastases involving 7 or more nodes\n\n
\nDistant Metastasis (M)\n \nM0 No distant metastasis\nM1 Distant metastasis\n\n
\nPrimary Tumor (T)\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor invades lamina propria or submucosa\nT2 Tumor invades muscularis propria\nT3 Tumor invades adventitia\nT4 Tumor invades adjacent structures\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nDistant Metastasis (M)\n\nMX Distant metastasis cannot be assessed\nM0 No distant metastasis\nM1 Distant metastasis\nM1a Metastasis in cervical nodes\nM1b Other distant metastasis\n\n
\nPrimary Tumor (T)\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor invades lamina propria or submucosa\nT2 Tumor invades muscularis propria\nT3 Tumor invades adventitia\nT4 Tumor invades adjacent structures\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nDistant Metastasis (M)\nFor tumors of midthoracic esophogus use\nonly M1b, since these tumors with metastasis\nin nonregional lymph nodes have an equally\npoor prognosis as those with metastasis in\nother distant sites.\n\nMX Distant metastasis cannot be assessed\nM0 No distant metastasis\nM1 Distant metastasis\nM1a Not applicable\nM1b Nonregional lymph nodes and/or other distant\n metastasis\n\n\n
\nPrimary Tumor (T)\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor invades lamina propria or submucosa\nT2 Tumor invades muscularis propria\nT3 Tumor invades adventitia\nT4 Tumor invades adjacent structures\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nDistant Metastasis (M)\n\nMX Distant metastasis cannot be assessed\nM0 No distant metastasis\nM1 Distant metastasis\nM1a Metastasis in celiac lymph nodes\nM1b Other distant metastasis\n\n
\nPrimary Tumor (T)\n without invasion of adjacent structures\nT4 Tumor invades adjacent structures\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ': intra-epithelial\n tumor without invasion of lamina propria\nT1 Tumor invades lamina propria or submucosa\nT2 Tumor invades muscularis propria or subserosa\nT3 Tumor penetrates serosa (visceral peritoneum)\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph node(s) cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in 1 to 6 regional lymph nodes\nN2 Metastasis in 7 to 15 regional lymph nodes\nN3 Metastasis in more than 15 regional lymph\n nodes\n\n
\nPrimary Tumor (T)\nT3 Tumor penetrates serosa (visceral peritoneum)\n without invasion of adjacent structures\nT4 Tumor invades adjacent structures\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ': intra-epithelial\n tumor without invasion of lamina propria\nT1 Tumor invades lamina propria or submucosa\nT2a Tumor invades muscularis propria\nT2b Tumor invades subserosa\n\n
\nPrimary Tumor (T)\nT2 Tumor invades muscularis propria\nT3 Tumor penetrates subserosal connective tissue without invasion of\n visceral peritoneum or adjacent structures\nT4 Tumor invades serosa (visceral peritoneum) or adjacent\n structures\nT4a Tumor invades serosa (visceral peritoneum)\nT4b Tumor invades adjacent structures\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ: intraepithelial tumor without invasion of the\n lamina propria\nT1 Tumor invades lamina propria, muscularis mucosae, or submucosa\nT1a Tumor invades lamina propria or muscularis mucosae\nT1b Tumor invades submucosa\n\n
\nRegional Lymph Nodes (N)\n \nNX Regional lymph node(s) cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in 1 to 2 regional lymph nodes\nN2 Metastasis in 3 to 6 regional lymph nodes\nN3 Metastasis in 7 or more regional lymph nodes\nN3a Metastasis in 7 to15 regional lymph nodes N3a\nN3b Metastasis in 16 or more regional lymph nodes\n\n
\n982 Primary site coded to C16.0\n May include cases which were converted to this code from a blank\n\n
\nInvolvement of Cardia and Distance from Esophagogastric Junction (EGJ)\n unknown \n050 Esophagus and EGJ not involved but distance of tumor midpoint from \n EGJ is 5cm or less \n060 Esophagus involved or esophagus involvement unknown AND distance of\n tumor midpoint from EGJ more than 5cm or unknown AND physician stages\n case using esophagus definitions \n100 OBSOLETE DATA RETAINED V0200\n C16.1, C16.2 - originally coded in CSv1\n999 Involvement of esophagus not stated, unknown or no information, not \n documented in patient record\n \n000 No involvement of esophagus or EGJ \n010 Tumor located in Cardia or EGJ \n020 Esophagus or EGJ involved AND distance of tumor midpoint from EGJ 5cm\n or less\n030 Esophagus or EGJ involved AND distance of tumor midpoint from EGJ \n more than 5cm \n040 Esophagus or EGJ involved AND distance of tumor midpoint from EGJ \n\n
\nInvolvement of Cardia and Distance from Esophagogastric Junction (EGJ)\n unknown \n050 Esophagus and EGJ not involved but distance of tumor midpoint from \n EGJ is 5cm or less \n060 Esophagus involved or esophagus involvement unknown AND distance of\n tumor midpoint from EGJ more than 5cm or unknown AND physician stages\n case using esophagus definitions \n100 OBSOLETE DATA RETAINED V0200\n C16.1, C16.2 - originally coded in CSv1 \n999 Involvement of esophagus not stated, unknown or no information, not \n documented in patient record\n \n000 No involvement of esophagus or EGJ \n010 Tumor located in Cardia or EGJ \n020 Esophagus or EGJ involved AND distance of tumor midpoint from EGJ 5cm\n or less\n030 Esophagus or EGJ involved AND distance of tumor midpoint from EGJ \n more than 5cm \n040 Esophagus or EGJ involved AND distance of tumor midpoint from EGJ \n\n
\nPrimary Tumor (T)\n perimuscular tissue (mesentery or retroperitoneum)\n with extension 2 cm or less\nT4 Tumor perforates the visceral peritoneum, or directly\n invades other organs or structures (includes other\n loops of small intestine, mesentery, or retroperitoneum\n more than 2 cm, and abdominal wall by way of serosa;\n for duodenum only, invasion of pancreas)\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor invades lamina propria or submucosa\nT2 Tumor invades muscularis propria\nT3 Tumor invades through the muscularis propria\n into the subserosa or into the nonperitonealized\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph node(s) cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\n into the nonperitonealized perimuscular tissue (mesentery or\n retroperitoneum) with extension 2 cm or less\nT4 Tumor perforates the visceral peritoneum or directly invades other\n organs or structures (includes other loops of small intestine,\n mesentery, or retroperitoneum more than 2 cm, and abdominal wall by\n way of serosa; for duodenum only, invasion of pancreas or bile duct)\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ\nT1a Tumor invades lamina propria\nT1b Tumor invades submucosa\nT2 Tumor invades muscularis propria\nT3 Tumor invades through the muscularis propria into the subserosa or\n\n
\nRegional Lymph Nodes (N)\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in 1 to 3 regional lymph nodes\nN2 Metastasis in 4 or more regional lymph nodes\n\n
\nPrimary Tumor (T)\n the subserosa, or into nonperitonealized pericolic\n or perirectal tissues\nT4 Tumor directly invades other organs or structures,\n and/or perforates visceral peritoneum\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ': intraepithelial or invasion of\n lamina propria\nT1 Tumor invades submucosa\nT2 Tumor invades muscularis propria\nT3 Tumor invades through the muscularis propria into\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph node(s) cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in 1 to 3 regional lymph nodes\nN2 Metastasis in 4 or more regional lymph nodes\n\n
\nPrimary Tumor (T)\nT4a Tumor penetrates to the surface of the visceral peritoneum\nT4b Tumor directly invades or is adherent to other organs or structures\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ: intraepithelial or invasion of lamina propria\nT1 Tumor invades submucosa\nT2 Tumor invades muscularis propria\nT3 Tumor invades through the muscularis propria into pericolorectal\n tissues\n\n
\nRegional Lymph Nodes (N)\nN2 Metastasis in 4 or more regional lymph nodes\nN2a Metastasis in 4 to 6 regional lymph nodes\nN2b Metastasis in 7 or more regional lymph nodes\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in 1 to 3 regional lymph nodes\nN1a Metastasis in 1 regional lymph node\nN1b Metastasis in 2-3 regional lymph nodes\nN1c Tumor deposit(s) in the subserosa, mesentery, or non-peritonealized\n pericolic or perirectal tissues without regional nodal metastasis\n\n
\nDistant Metastasis (M)\n \nM0 No distant metastasis\nM1a Metastasis confined to one organ or site (e.g., liver, lung, ovary, \n non-regional node)\nM1b Metastases in more than one organ/site or the peritoneum\n\n
\nPrimary Tumor (T)\n mesoappendix\nT4 Tumor penetrates visceral peritoneum, including mucinous peritoneal\n tumor within the right lower quadrant and/or directly invades other\n organs or structures\nT4a Tumor penetrates visceral peritoneum, including mucinous peritoneal\n tumor within the right lower quadrant\nT4b Tumor directly invades other organs or structures\n \nCarcinoma\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ: intraepithelial or invasion of lamina propria *\nT1 Tumor invades submucosa\nT2 Tumor invades muscularis propria\nT3 Tumor invades through muscularis propria into subserosa or into \n\n
\nRegional Lymph Nodes (N)\n \nCarcinoma\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in 1 to 3 regional lymph nodes\nN2 Metastasis in 4 or more regional lymph nodes\n\n
\nDistant Metastasis (M)\n \nCarcinoma\nM0 No distant metastasis\nM1a Intraperitoneal metastasis beyond the right lower quadrant, including\n pseudomyxoma peritonei\nM1b Non-peritoneal metastasis\n\n
\nPrimary Tumor (T)\nT4 Tumor of any size invades adjacent organ(s),\n e.g., vagina, urethra, bladder (involvement\n of the sphincter muscle(s) alone is not\n classified as T4)\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor 2 cm or less in greatest dimension\nT2 Tumor more than 2 cm but not more than\n 5 cm in greatest dimension\nT3 Tumor more than 5 cm in greastest dimension\n\n
\nRegional Lymph Nodes (N)\n iliac and/or inguinal lymph nodes\n\nNX Regional lymph node(s) cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in perirectal lymph node(s)\nN2 Metastasis in unilateral internal iliac\n and/or inguinal lymph node(s)\nN3 Metastasis in perirectal and inguinal\n lymph nodes and/or bilateral internal\n\n
\nPrimary Tumor (T)\nT3 Tumor more than 5 cm in greatest dimension\nT4 Tumor of any size invades adjacent organ(s), e.g., vagina, urethra, \n bladder\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ (Bowen's disease, High-grade Squamous\n Intraepithelial Lesion (HSIL), Anal Intraepithelial Neoplasia\n II-III (AIN II-III)\nT1 Tumor 2 cm or less in greatest dimension\nT2 Tumor more than 2 cm but not more than 5 cm in greatest dimension\n\n
\nRegional Lymph Nodes (N)\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in perirectal lymph node(s)\nN2 Metastasis in unilateral internal iliac and/or inguinal lymph node(s)\nN3 Metastasis in perirectal and inguinal lymph nodes and/or bilateral \n internal iliac and/or inguinal lymph nodes\n\n
\nPrimary Tumor (T)\n a solitary tumor more than 2 cm in greatest dimension without\n vascular invasion\nT3 Solitary tumor more than 2 cm in greatest dimension with vascular\n invasion, or multiple tumors limited to one lobe, none more than\n 2 cm in greatest dimension, with vascular invasion, or a multiple\n tumors limited to one lobe, any more than 2 cm in greatest\n dimension, with or without vascular invasion\nT4 Multiple tumors in more than one lobe or tumor(s) involve(s) a major\n branch of the portal or hepatic vein(s) or invasion of adjacent\n organs other than the gallbladder or perforation of the visceral\n \n peritoneum\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Solitary tumor 2 cm or less in greatest dimension without vascular\n invasion\nT2 Solitary tumor 2 cm or less in greatest dimension with vascular\n invasion, or multiple tumors limited to one lobe, none more\n than 2 cm in greatest dimension without vascular invasion, or\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph node(s) cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\n vein(s)\nT4 Tumor(s) with direct invasion of adjacent\n organs other than the gallbladder or with\n perforation of visceral peritoneum\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Solitary tumor without vascular invasion\nT2 Solitary tumor with vascular invasion or\n multiple tumors none more than 5 cm\nT3 Multiple tumors more than 5 cm or tumor\n involving a major branch of the portal or hepatic\n\n
\nPrimary Tumor (T)\n of the portal vein or hepatic vein\nT4 Tumor(s) with direct invasion of adjacent organs other than the \n gallbladder or with perforation of visceral peritoneum\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Solitary tumor without vascular invasion\nT2 Solitary tumor with vascular invasion or multiple tumors none more\n than 5 cm\nT3a Multiple tumors more than 5 cm\nT3b Single tumor or multiple tumors of any size involving a major branch\n\n
\nPrimary Tumor (T)\n extra hepatic structures by direct invasion\nT4 Tumor with periductal invasion\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ (intraductal tumor)\nT1 Solitary tumor without vascular invasion\nT2a Solitary tumor with vascular invasion\nT2b Multiple tumors, with or without vascular invasion\nT3 Tumor perforating the visceral peritoneum or involving the local\n\n
\nRegional Lymph Nodes (N)\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis present \n\n
\nDistant Metastasis (M)\n \nM0 No distant metastasis\nM1 Distant metastasis present\n\n
\nPrimary Tumor (T)\n no extension beyond serosa or into liver\nT3 Tumor perforates the serosa (visceral\n peritoneum) or directly invades one adjacent\n organ, or both (extension 2 cm or less into\n liver)\nT4 Tumor extends more than 2 cm into liver, and/or\n into two or more adjacent organs (stomach,\n duodenum, colon, pancreas, omentum, extrahepatic\n bile ducts, any involvement of liver)\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor invades lamina propria or muscle layer\nT1a Tumor invades lamina propria\nT1b Tumor invades muscle layer\nT2 Tumor invades perimuscular connective tissue;\n\n
\nRegional Lymph Nodes (N)\n superior mesentric lymph nodes\n\nNX Regional lymph node(s) cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in cystic duct, pericholedochal,\n and/or hilar lymph nodes (i.e., in the\n hepatoduodenal ligament)\nN2 Metastasis in peripancreatic (head only),\n peridoudenal, periportal, celiac, and/or\n\n
\nPrimary Tumor (T)\n extension beyond serosa or into liver\nT3 Tumor perforates the serosa (visceral peritoneum)\n and/or directly invades the liver and/or one other\n adjacent organ or structure, such as the stomach,\n duodenum, colon, or pancreas, omentum or extra-\n hepatic bile ducts\nT4 Tumor invades main portal vein or hepatic artery\n or invades multiple extrahepatic organs or struc-\n tures\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor invades lamina propria or muscle layer\nT1a Tumor invades lamina propria\nT1b Tumor invades muscle layer\nT2 Tumor invades perimuscular connective tissue; no\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph node(s) cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\n serosa or into liver\nT3 Tumor perforates the serosa (visceral peritoneum) and / or directly \n invades the liver and/or one other adjacent organ or structure, such\n as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic\n bile ducts\nT4 Tumor invades main portal vein or hepatic artery or invades two or\n more extrahepatic organs or structures\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ\nT1 Tumor invades lamina propria or muscular layer\nT1a Tumor invades lamina propria\nT1b Tumor invades muscular layer\nT2 Tumor invades perimuscular connective tissue; no extension beyond\n\n
\nRegional Lymph Nodes (N)\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastases to nodes along the cystic duct, common bile duct, hepatic \n artery, and/or portal vein.\nN2 Metastases to periaortic, pericaval, superior mesentery artery and/or\n celiac artery lymph nodes\n\n
\nDistant Metastasis (M)\n \nM0 No distant metastasis\nM1 Distant metastasis\n\n
\nPrimary Tumor (T)\nT1b Tumor invades fibromuscular layer\nT2 Tumor invades perifibromuscular connective\n tissue\nT3 Tumor invades adjacent structures: liver,\n pancreas, duodenum, gallbladder, colon,\n stomach\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor invades subepithelial connective\n tissue or fibromuscular layer\nT1a Tumor invades subepithelial connective\n tissue\n\n
\nRegional Lymph Nodes (N)\n superior mesentric and/or posterior\n pancreaticoduodenal lymph nodes\n\nNX Regional lymph node(s) cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in cystic duct, pericholedochal\n and/or hilar lymph nodes (i.e., in the\n hepatoduodenal ligament)\nN2 Metastasis in peripancreatic (head only),\n peridoudenal, periportal, celiac, and/or\n\n
\nPrimary Tumor (T)\n left) or hepatic artery (right or left)\nT4 Tumor invades any of the following: main portal\n vein or its branches bilaterally, common hepatic ar-\n tery, or other adjacent structures, such as the colon,\n stomach, duodenum, or abdominal wall \n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor confined to the bile duct histologically\nT2 Tumor invades beyond the wall of the bile duct\nT3 Tumor invades the liver, gallbladder, pancreas, and/\n or unilateral branches of the portal vein (right or\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\nT2b Tumor invades adjacent hepatic parenchyma\nT3 Tumor invades unilateral branches of the portal vein or hepatic\n artery\nT4 Tumor invades main portal vein or its branches bilaterally; or the\n common hepatic artery; or the second-order biliary radicals\n bilaterally; or unilateral second-order biliary radicals with\n contralateral portal vein or hepatic artery involvement\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ\nT1 Tumor confined to the bile duct, with extension up to the muscle\n layer or fibrous tissue\nT2a Tumor invades beyond the wall of the bile duct to surrounding adipose\n tissue \n\n
\nRegional Lymph Nodes (N)\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis (including nodes along the cystic\n duct, common bile duct, hepatic artery, and portal vein)\nN2 Metastasis to periaortic, pericaval, superior mesentery artery,\n and/or celiac artery lymph nodes\n\n
\nSchema Discriminator: Subsite of Extrahepatic Bile Ducts\n050 Diffuse involvement \n More than one subsite involved, subsite of origin not stated \n060 Subsite of extrahepatic bile ducts not stated, but treated with \n combined hepatic and hilar resection\n070 Subsite of extrahepatic bile ducts not stated, but treated with \n pancreaticoduodenectomy \n100 OBSOLETE DATA RETAINED V0200\n C24.0 - originally coded in CSv1\n999 Subsite of extrahepatic bile ducts not stated and not classifiable in\n codes 050-070 \n \n010 Perihilar bile duct(s)\n Proximal extrahepatic bile duct(s)\n Hepatic duct(s) \n020 Stated as Klatskin tumor \n030 Cystic bile duct; cystic duct \n040 Common bile duct\n Common duct, NOS \n\n
\nPrimary Tumor (T)\nT4 Tumor invades more than 2 cm into pancreas\n and/or into other adjacent organs\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor limited to the ampulla of Vater\n or sphincter of Oddi\nT2 Tumor invades duodenal wall\nT3 Tumor invades 2 cm or less into the pancreas\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph node(s) cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\nT4 Tumor invades peripancreatic soft tissues or other\n adjacent organs or structures\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor limited to the ampulla of Vater or sphincter of\n Oddi\nT2 Tumor invades duodenal wall\nT3 Tumor invades pancreas\n\n
\nPrimary Tumor (T)\nT3 Tumor extends directly into any of the following:\n duodenum, bile duct, peripancreatic tissues\nT4 Tumor extends directly into any of the following:\n stomach, spleen, colon, adjacent large vessels\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis 'In situ' carcinoma\nT1 Tumor limited to the pancreas 2 cm or less\n in greatest dimension\nT2 Tumor limited to the pancreas more than\n 2 cm in greatest dimension\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph node(s) cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\nN1a Metastasis in a single regional lymph node\nN1b Metastasis in multiple regional lymph nodes\n\n
\nPrimary Tumor (T)\nT3 Tumor extends beyond the pancreas but without\n involvement of the celiac axis or the superior\n mesenteric artery\nT4 Tumor involves the celiac axis or the superior\n mesenteric artery (unresectable primary tumor) \n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor limited to the pancreas, 2 cm or less in\n greatest dimension\nT2 Tumor limited to the pancreas, more than 2 cm in\n greatest dimension\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\n palate and/or the middle nasal meatus\nT3 Tumor invades any of the following: bone of the posterior\n wall of maxillary sinus, subcutaneous tissues, skin of\n cheek, floor or medial wall of orbit, infratemporal\n fossa, pterygoid plates, ethmoid sinuses\nT4 Tumor invades orbital contents beyond the floor or medial\n wall including any of the following: the orbital apex,\n cribriform plate, base of skull, nasopharynx, sphenoid,\n frontal sinuses\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor limited to the antral mucosa with no erosion or\n destruction of bone\nT2 Tumor causing bone erosion or destruction, except for the\n posterior antral wall, including extension into the hard\n\n
\nRegional Lymph Nodes (N)\n greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes,\n none more than 6 cm in greatest dimension\nN2c Metastasis in bilateral or contralateral lymph\n nodes, none more than 6 cm in greatest dimension\nN3 Metastasis in a lymph node more than 6 cm in\n greatest dimension\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node,\n 3 cm or less in greatest dimension\nN2 Choose from N2a, N2b or N2c\nN2a Metastasis in a single ipsilateral lymph node\n more than 3 cm but not more than 6 cm in\n\n
\nPrimary Tumor (T)\n middle nasal meatus, except extension to posterior\n wall of maxillary sinus and pterygoid plates\nT3 Tumor invades any of the following: bone of the posterior\n wall of maxillary sinus, subcutaneous tissues, skin of\n cheek, floor or medial wall of orbit, infratemporal\n fossa, pterygoid plates, ethmoid sinuses\nT4a Tumor invades any of the following:\n anterior orbital contents, skin of nose or cheek,\n minimal extension to anterior fossa, pterygoid,\n plates, sphenoid or frontal sinuses\n \nT4b Tumor invades any of the following: orbital\n apex, dura, brain, middle cranial fossa, cranial\n other than (V2), nasopharynx, or clivus\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor limited to maxillary sinus mucosa\n with no erosion or destruction of bone\nT2 Tumor causing bone erosion or destruction\n including extension into the hard palate and/or\n\n
\nPrimary Tumor (T)\n posterior wall of maxillary sinus and pterygoid plates\nT3 Tumor invades any of the following: bone of the posterior wall of \n maxillary sinus, subcutaneous tissues, floor or medial wall of\n orbit, pterygoid fossa, ethmoid sinuses\nT4a Moderately advanced local disease.\n Tumor invades anterior orbital contents, skin of cheek, pterygoid\n plates, infratemporal fossa, cribriform plate, sphenoid or frontal\n sinuses\nT4b Very advanced local disease.\n Tumor invades any of the following: orbital apex, dura, brain,\n \n middle cranial fossa, cranial nerves other than maxillary division\n of trigeminal nerve (V2), nasopharynx, or clivus\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Tis Carcinoma in situ\nT1 Tumor limited to maxillary sinus mucosa with no erosion or\n destruction of bone\nT2 Tumor causing bone erosion or destruction including extension into\n the hard palate and/or middle nasal meatus, except extension to\n\n
\nRegional Lymph Nodes (N)\n bilateral or contralateral lymph nodes, none more than 6 cm in\n greatest dimension\nN2a Metastasis in a single ipsilateral lymph node, more than 3 cm but not\n more than 6 cm in greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm\n in greatest dimension\nN2d Metastasis in bilateral or contralateral lymph nodes, none more than\n 6 cm in greatest dimension\nN3 Metastasis in a lymph node, more than 6 cm in greatest dimension\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node, 3 cm or less in\n greatest dimension\nN2 Metastasis in a single ipsilateral lymph node, more than 3 cm but not\n more than 6 cm in greatest dimension, or in multiple ipsilateral\n lymph nodes, none more than 6 cm in greatest dimension, or in\n\n
\nPrimary Tumor (T)\n and/or maxillary sinus\nT4 Tumor with intracranial extension,\n orbital extension including apex,\n involving sphenoid, and/or frontal\n sinus and/or skin of external nose\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor confined to the ethmoid with\n or without bone erosion\nT2 Tumor extends into the nasal cavity\nT3 Tumor extends to the anterior orbit,\n\n
\nRegional Lymph Nodes (N)\n greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes,\n none more than 6 cm in greatest dimension\nN2c Metastasis in bilateral or contralateral lymph\n nodes, none more than 6 cm in greatest dimension\nN3 Metastasis in a lymph node more than 6 cm in\n greatest dimension\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node,\n 3 cm or less in greatest dimension\nN2 Choose from N2a, N2b or N2c\nN2a Metastasis in a single ipsilateral lymph node\n more than 3 cm but not more than 6 cm in\n\n
\nPrimary Tumor (T)\n the nasoethmoidal complex, with or without bony\n invasion\nT3 Tumor extends to invade the medial wall or\n floor of the orbit, maxillary sinus, palate, or\n cribriform plate\nT4a Tumor invades any of the following:\n anterior orbital contents, skin of nose or cheek,\n minimal extension to anterior fossa, pterygoid,\n plates, sphenoid or frontal sinuses\nT4b Tumor invades any of the following: orbital\n \n apex, dura, brain, middle cranial fossa, cranial\n nerves other than (V2), nasopharynx, or clivus\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor restricted to any 1 subsite, with or\n without bony invasion\nT2 Tumor invading 2 subsites in a single region\n or extending to involve an adjacent region within\n\n
\nPrimary Tumor (T)\nT3 Tumor extends to invade the medial wall or floor of the orbit,\n maxillary sinus, palate, or cribriform plate\nT4a Moderately advanced local disease.\n Tumor invades any of the following: anterior orbital contents, skin\n of nose or cheek, minimal extension to anterior cranial fossa,\n pterygoid plates, sphenoid or frontal sinuses\nT4b Very advanced local disease.\n Tumor invades any of the following: orbital apex, dura, brain,\n middle cranial fossa, cranial nerves other than (V2), nasopharynx,\n or clivus\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Tis Carcinoma in situ\nT1 Tumor restricted to any one subsite, with or without bony invasion\nT2 Tumor invading two subsites in a single region or extending to\n involve an adjacent region within the nasoethmoidal complex, with or\n without bony invasion\n\n
\nRegional Lymph Nodes (N)\n bilateral or contralateral lymph nodes, none more than 6 cm in\n greatest dimension\nN2a Metastasis in a single ipsilateral lymph node, more than 3 cm but not\n more than 6 cm in greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm\n in greatest dimension\nN2c Metastasis in bilateral or contralateral lymph nodes, none more than\n 6 cm in greatest dimension\nN3 Metastasis in a lymph node, more than 6 cm in greatest dimension\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node, 3 cm or less in\n greatest dimension\nN2 Metastasis in a single ipsilateral lymph node, more than 3 cm but not\n more than 6 cm in greatest dimension, or in multiple ipsilateral\n lymph nodes, none more than 6 cm in greatest dimension, or in\n\n
\nPrimary Tumor (T)\nT1b Tumor involves both vocal cords\nT2 Tumor extends to supraglottis and/or subglottis,\n and/or with impaired vocal cord mobility\nT3 Tumor limited to the larynx with vocal cord\n fixation\nT4 Tumor invades through the thyroid cartilage\n and/or to other tissues beyond the larynx (e.g.,\n trachea, soft tissues of the neck, including\n thyroid, pharynx)\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor limited to the vocal cord(s) (may involve\n anterior or posterior commissure) with normal\n mobility\nT1a Tumor limited to one vocal cord\n\n
\nRegional Lymph Nodes (N)\n greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes,\n none more than 6 cm in greatest dimension\nN2c Metastasis in bilateral or contralateral lymph\n nodes, none more than 6 cm in greatest dimension\nN3 Metastasis in a lymph node more than 6 cm in\n greatest dimension\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node,\n 3 cm or less in greatest dimension\nN2 Choose from N2a, N2b or N2c\nN2a Metastasis in a single ipsilateral lymph node\n more than 3 cm but not more than 6 cm in\n\n
\nPrimary Tumor (T)\nT1b Tumor involves both vocal cords\nT2 Tumor extends to supraglottis and/or subglottis,\n and/or with impaired vocal cord mobility\nT3 Tumor limited to the larynx with vocal cord\n fixation\nT4a Tumor invades through the thyroid cartilage\n and/or invades tissues beyond the larynx (eg,\n trachea, soft tissues of the neck including deep\n extrinsic muscle of the tongue, strap muscles,\n thyroid, or esophagus)\n \nT4b Tumor invades prevertebral space, encases\n carotid artery, or invades mediastinal structures\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor limited to the vocal cord(s) (may involve\n anterior or posterior commissure) with normal\n mobility\nT1a Tumor limited to one vocal cord\n\n
\nPrimary Tumor (T)\nT2 Tumor extends to supraglottis and/or subglottis, and/or with impaired\n vocal cord mobility\nT3 Tumor limited to the larynx with vocal cord fixation and/or invasion\n of paraglottic space, and/or inner cortex of the thyroid cartilage\nT4a Moderately advanced local disease.\n Tumor invades through the outer cortex of the thyroid cartilage\n and/or invades tissues beyond the larynx (e.g., trachea, soft\n tissues of neck including deep extrinsic muscle of the tongue,\n strap muscles, thyroid, or esophagus)\nT4b Very advanced local disease.\n \n Tumor invades prevertebral space, encases carotid artery, or\n invades mediastinal structures\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ\nT1 Tumor limited to the vocal cord(s) (may involve anterior or posterior\n commissure) with normal mobility\nT1a Tumor limited to one vocal cord\nT1b Tumor involves both vocal cords\n\n
\nRegional Lymph Nodes (N)\n bilateral or contralateral lymph nodes, none more than 6 cm in\n greatest dimension\nN2a Metastasis in a single ipsilateral lymph node, more than 3 cm but not\n more than 6 cm in greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm\n in greatest dimension\nN2c Metastasis in bilateral or contralateral lymph nodes, none more than\n 6 cm in greatest dimension\nN3 Metastasis in a lymph node, more than 6 cm in greatest dimension\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node, 3 cm or less in\n greatest dimension\nN2 Metastasis in a single ipsilateral lymph node, more than 3 cm but not\n more than 6 cm in greatest dimension, or in multiple ipsilateral\n lymph nodes, none more than 6 cm in greatest dimension, or in\n\n
\nPrimary Tumor (T)\n outside the supraglottis (e.g., mucosa of base\n of tongue, vallecula, medial wall of pyriform\n sinuses) without fixation of the larynx\nT3 Tumor limited to larynx with vocal cord\n fixation and/or invades any of the following:\n postcricoid area, pre-epiglottic tissues\nT4 Tumor invades through the thyroid cartilage,\n and/or extends into soft tissues of the neck,\n thyroid, and/or esophagus\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor limited to one subsite of supraglottis\n with normal vocal cord mobility\nT2 Tumor invades mucosa of more than one adjacent\n subsite of supraglottis or glottis or region\n\n
\nRegional Lymph Nodes (N)\n greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes,\n none more than 6 cm in greatest dimension\nN2c Metastasis in bilateral or contralateral lymph\n nodes, none more than 6 cm in greatest dimension\nN3 Metastasis in a lymph node more than 6 cm in\n greatest dimension\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node,\n 3 cm or less in greatest dimension\nN2 Choose from N2a, N2b or N2c\nN2a Metastasis in a single ipsilateral lymph node\n more than 3 cm but not more than 6 cm in\n\n
\nPrimary Tumor (T)\n outside the supraglottis (e.g., mucosa of base\n of tongue, vallecula, medial wall of pyriform\n sinuses) without fixation of the larynx\nT3 Tumor limited to larynx with vocal cord\n fixation and/or invades any of the following:\n postcricoid area, pre-epiglottic tissues,\n paraglottic space, and/or minor thyroid\n cartilage erosion (e.g. inner cortex)\nT4a Tumor invades through the thyroid cartilage\n and/or invades tissues beyond the larynx (eg,\n \n trachea, soft tissues of the neck including deep\n extrinsic muscle of the tongue, strap muscles,\n thyroid, or esophagus)\nT4b Tumor invades prevertebral space, encases\n carotid artery, or invades mediastinal structures\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor limited to one subsite of supraglottis\n with normal vocal cord mobility\nT2 Tumor invades mucosa of more than one adjacent\n subsite of supraglottis or glottis or region\n\n
\nPrimary Tumor (T)\n mucosa of base of tongue, vallecula, medial wall of pyriform sinus)\n without fixation of the larynx\nT3 Tumor limited to larynx with vocal cord fixation and/or invades any\n of the following: postcricoid area, pre-epiglottic space,\n paraglottic space, and/or inner cortex of thyroid cartilage.\nT4a Moderately advanced local disease.\n Tumor invades through the thyroid cartilage and /or invades tissues\n beyond the larynx (e.g., trachea, soft tissues of neck including\n deep extrinsic muscle of the tongue, strap muscles, thyroid, or\n esophagus)\n \nT4b Very advanced local disease.\n Tumor invades prevertebral space, encases carotid artery, or\n invades mediastinal structures\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ\nT1 Tumor limited to one subsite of supraglottis with normal vocal cord \n mobility\nT2 Tumor invades mucosa of more than one adjacent subsite of\n supraglottis or glottis or region outside the supraglottis (e.g.,\n\n
\nRegional Lymph Nodes (N)\n bilateral or contralateral lymph nodes, none more than 6 cm in\n greatest dimension\nN2a Metastasis in a single ipsilateral lymph node, more than 3 cm but not\n more than 6 cm in greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm\n in greatest dimension\nN2c Metastasis in bilateral or contralateral lymph\n nodes, none more than 6 cm in greatest dimension\nN3 Metastasis in a lymph node, more than 6 cm in greatest dimension\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node, 3 cm or less in\n greatest dimension\nN2 Metastasis in a single ipsilateral lymph node, more than 3 cm but not\n more than 6 cm in greatest dimension, or in multiple ipsilateral\n lymph nodes, none more than 6 cm in greatest dimension, or in\n\n
\nPrimary Tumor (T)\n vocal cord fixation\nT4 Tumor invades through cricoid or thyroid\n cartilage and/or extends to other tissues\n beyond the larynx (e.g., trachea, soft\n tissues of the neck, including thyroid, pharynx)\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor limited to the subglottis\nT2 Tumor extends to vocal cord(s) with\n normal or impaired mobility\nT3 Tumor limited to the larynx with\n\n
\nRegional Lymph Nodes (N)\n greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes,\n none more than 6 cm in greatest dimension\nN2c Metastasis in bilateral or contralateral lymph\n nodes, none more than 6 cm in greatest dimension\nN3 Metastasis in a lymph node more than 6 cm in\n greatest dimension\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node,\n 3 cm or less in greatest dimension\nN2 Choose from N2a, N2b or N2c\nN2a Metastasis in a single ipsilateral lymph node\n more than 3 cm but not more than 6 cm in\n\n
\nPrimary Tumor (T)\n vocal cord fixation\nT4a Tumor invades cricoid or thyroid cartilage\n and/or invades tissues beyond the larynx (eg,\n trachea, soft tissues of the neck including deep\n extrinsic muscle of the tongue, strap muscles,\n thyroid, or esophagus)\nT4b Tumor invades prevertebral space, encases\n carotid artery, or invades mediastinal structures\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor limited to the subglottis\nT2 Tumor extends to vocal cord(s) with\n normal or impaired mobility\nT3 Tumor limited to the larynx with\n\n
\nPrimary Tumor (T)\n Tumor invades cricoid or thyroid cartilage and/or invades tissues\n beyond the larynx (e.g., trachea, soft tissues of neck including\n deep extrinsic muscles of the tongue, strap muscles, thyroid, or\n esophagus)\nT4b Very advanced local disease.\n Tumor invades prevertebral space, encases carotid artery, or\n invades mediastinal structures\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ\nT1 Tumor limited to the subglottis\nT2 Tumor extends to vocal cord(s) with normal or impaired mobility\nT3 Tumor limited to larynx with vocal cord fixation\nT4a Moderately advanced local disease.\n\n
\nRegional Lymph Nodes (N)\n bilateral or contralateral lymph nodes, none more than 6 cm in\n greatest dimension\nN2a Metastasis in a single ipsilateral lymph node, more than 3 cm but not\n more than 6 cm in greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm\n in greatest dimension Metastasis in bilateral or contralateral lymph\n nodes, none more than 6 cm in greatest dimension\nN3 Metastasis in a lymph node, more than 6 cm in greatest dimension\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node, 3 cm or less in\n greatest dimension\nN2 Metastasis in a single ipsilateral lymph node, more than 3 cm but not\n more than 6 cm in greatest dimension, or in multiple ipsilateral\n lymph nodes, none more than 6 cm in greatest dimension, or in\n\n
\nPrimary Tumor (T)\n proximal than the lobar bronchus, (i.e.,not in the main bronchus)\nT2 Tumor with any of the following features of size or extent:\n More than 3 cm in greatest dimension\n Involves main bronchus, 2 cm or more distal to the carina\n Invades the visceral pleura\n Associated with atelectasis or obstructive pneumonitis that extends\n to the hilar region but does not involve the entire lung\nT3 Tumor of any size that directly invades any of the following: chest wall,\n (including superior sulcus tumors), diaphragm, medistinal pleura,\n parietal pericardium; or tumor in the main bronchus less than 2 cm\n \n distal to the carina, but without involvement of the carina; or\n associated atelectasis or obstructive pneumonitis of the entire lung\nT4 Tumors of any size that invades any of the following: mediastinum, heart,\n great vessels, trachea, esophagus, vertebral body, carina; or separate\n tumor nodules in the same lobe; or tumor with a malignant pleural\n effusion\nTX Primary tumor cannot be assessed, or tumor proven by the presence of\n malignant cells in sputum or bronchial washings but not visualized\n by imaging or bronchoscopy\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor 3 cm or less in greatest dimension, surrounded by lung or\n visceral pleura, without bronchoscopic evidence of invasion more\n\n
\nRegional Lymph Nodes (N)\nN2 Metastasis to ipsilateral mediastinal and/or\n subcarinal lymph node(s)\nN3 Metastasis to contralateral mediastinal,\n contralateral hilar, ipsilateral or \n contralateral scalene, or supraclavicular\n lymph node(s)\n\nNX Regional lymph node(s) cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis to ipsilateral peribronchial\n and/or ipsilateral hilar lymph nodes,\n and intrapulmonary nodes including \n involvement by direct extension of the\n primary tumor\n\n
\nDistant Metastasis (M)\n\nMX Distant metastasis cannot be assessed\nM0 No distant metastasis\nM1 Distant metastasis present\n\nNote: M1 includes separate tumor nodule(s) in a\n different lobe (ipsilateral or contralateral).\n\n
\nPrimary Tumor (T)\nT1b Tumor > 2 cm but < or = 3 cm in greatest dimension\nT2 Tumor > 3 cm but < or = 7 cm or tumor with any of the following\n features (T2 tumors with these features are classified T2a if < or =\n 5 cm)\n Involves main bronchus, > or = 2 cm distal to the carina\n Invades visceral pleura (PL1 or PL2)\n Associated with atelectasis or obstructive pneumonitis that extends\n to the hilar region but does not involve the entire lung\nT2a Tumor > 3 cm but < or = 5 cm in greatest dimension\nT2b Tumor > 5 cm but < or = 7 cm in greatest dimension\n \nT3 Tumor > 7 cm or one that directly invades any of the following:\n parietal pleural (PL3) chest wall (including superior sulcus\n tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal\n pericardium; or tumor in the main bronchus (< 2 cm distal to the\n carina but without involvement of the carina; or associated\n atelectasis or obstructive pneumonitis of the entire lung or\n separate tumor nodule(s) in the same lobe\nT4 Tumor of any size that invades any of the following: mediastinum,\n heart, great vessels, trachea, recurrent laryngeal nerve, esophagus,\n vertebral body, carina, separate tumor nodule(s) in a different\nTX Primary tumor cannot be assessed\n ipsilateral lobe\nT0 No evidence of primary tumor\nTis Carcinoma in situ\nT1 Tumor < or = 3 cm in greatest dimension, surrounded by lung or\n visceral pleura, without bronchoscopic evidence of invasion more\n proximal than the lobar bronchus (i.e., not in the main bronchus)\nT1a Tumor < or = 2 cm in greatest dimension\n\n
\nDistant Metastasis (M)\n \nM0 No distant metastasis\nM1 Distant metastasis\nM1a Separate tumor nodule(s) in a contralateral lobe; tumor with pleural \n nodules or malignant pleural (or pericardial) effusion\nM1b Distant metastasis (in extrathoracic organs)\n\n
\nPrimary Tumor (T)\nT3 Tumor invades any of the following:\n ipsilateral chest wall muscle, ribs,\n mediastinal organs or tissues\nT4 Tumor directly extends to any of the following:\n contralateral pleura, lung, peritoneum,\n intra-abdominal organs, or cervical tissues\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor limited to ipsilateral parietal\n and/or visceral pleura\nT2 Tumor invades any of the following:\n ipsilateral lung, endothoracic fascia,\n diaphragm, pericardium\n\n
\nRegional Lymph Nodes (N)\nN3 Metastasis in contralateral mediastinal,\n contralateral hilar, ipsilateral or \n contralateral scalene, or supraclavicular\n lymph node(s)\n\nNX Regional lymph node(s) cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in ipsilateral peribronchial\n and/or ipsilateral hilar lymph nodes,\n including direct extension\nN2 Metastasis in ipsilateral mediastinal and/or\n subcarinal lymph node(s)\n\n
\nPrimary Tumor (T)\n with focal involvement of visceral pleura\n Tumor involves any of the ipsilateral pleural surfaces with at least one\n of the following:\nT2 - confluent visceral pleural tumor (including fissure)\n - invasion of diaphragmatic muscle\n - invasion of lung parenchyma\nT3 - invasion of the endothoracic fascia\n - invasion into mediastinal fat\n - solitary focus of tumor invading the soft tissues of the chest wall\n - non-transmural involvement of the pericardium\n\nT4 - diffuse or multifocal invasion of soft tissues of the chest wall\n - any involvement of rib\n - invasion through the diaphragm to the peritoneum\n - invasion of any mediastinal organ(s)\n - direct extension to the contralateral pleura\n - invasion into the spine\n - extension to the internal surface of the pericardium\n - pericardial effusion with positive cytology\n - invasion of the myocardium\n - invasion of the brachial plexus\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor involves ipsilateral parietal pluera, with or without focal\n involvement of visceral pleura\nT1a Tumor involves ipsilateral parietal (mediastinal, diaphragmatic) pleura\n No involvement of visceral pleura\nT1b Tumor involves ipsilateral parietal (mediastinal, diaphragmatic) pleura\n\n
\nRegional Lymph Nodes (N)\nN3 Metastasis in contralateral mediastinal, internal\n mammary, or hilar lymph node(s) and/or the\n ipsilateral or contralateral supraclavicular or\n scalene lymph node(s)\n\nNX Regional lymph node(s) cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in the ipsilateral bronchopulmonary\n and/or hilar lymph node(s)\nN2 Metastasis in the subcarinal lymph node(s)\n and/or the ipsilateral internal mammary or mediastinal\n lymph node(s)\n\n
\nPrimary Tumor (T)\nT2 Tumor involving each of the ipsilateral pleural surfaces (parietal, \n mediastinal, diaphragmatic, and visceral pleura) with at least one\n of the following features:\n involvement of diaphragmatic muscle\n extension of tumor from visceral pleura into the underlying\n pulmonary parenchyma\nT3 Locally advanced but potentially resectable tumor\n Tumor involving all of the ipsilateral pleural surfaces (parietal, \n mediastinal, diaphragmatic, and visceral pleura) with at least one\n of the following features:\n \n involvement of the endothoracic fascia\n extension into the mediastinal fat\n solitary, completely resectable focus of tumor extending into the\n soft tissues of the chest wall\n non-transmural involvement of the pericardium\nT4 Locally advanced technically unresectable tumor\n Tumor involving all of the ipsilateral pleural surfaces (parietal, \n mediastinal, diaphragmatic, and visceral pleura) with at least one\n of the following features:\n diffuse extension or multifocal masses of tumor in the chest\nTX Primary tumor cannot be assessed\n wall, with or without associated rib destruction\n direct transdiaphragmatic extension of tumor to the peritoneum\n direct extension of tumor to the contralateral pleura\n direct extension of tumor to mediastinal organs\n direct extension of tumor into the spine\n tumor extending through to the internal surface of the\n pericardium with or without a pericardial effusion; or tumor\n involving the myocardium\nT0 No evidence of primary tumor\nT1 Tumor limited to the ipsilateral parietal pleura with or without \n media stinal pleura and with or without diaphragmatic pleural\n involvement\nT1a No involvement of the visceral pleura\nT1b Tumor also involving the visceral pleura\n\n
\nRegional Lymph Nodes (N)\n mammary, ipsilateral or contralateral supraclavicular lymph nodes\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastases\nN1 Metastases in the ipsilateral bronchopulmonary or hilar lymph nodes\nN2 Metastases in the subcarinal or the ipsilateral mediastinal lymph\n nodes including the ipsilateral internal mammary and\n peridiaphragmatic nodes\nN3 Metastases in the contralateral mediastinal, contralateral internal \n\n
\nPrimary Tumor (T)\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor confined within the cortex\nT2 Tumor invades beyond the cortex\n\n
\nRegional Lymph Nodes (N)\nconsidered N0 if no clinical involvement\nis evident.\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\nNote: Because of the rarity of lymph node\ninvolvement in sarcomas, the designation\nNX may not be appropriate and could be\n\n
\nPrimary Tumor (T)\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor 8 cm or less in greatest dimension\nT2 Tumor more than 8 cm in greatest dimension\nT3 Discontinuous tumors in the primary bone site\n\n
\nDistant Metastasis (M)\n\nMX Distant metastasis cannot be assessed\nM0 No distant metastasis\nM1 Distant metastasis\nM1a Lung\nM1b Other distant sites\nM88 NA\n\n
\nPrimary Tumor (T)\nT4 Tumor invades deep extradermal structures\n (i.e., cartilage, skeletal muscle, or bone)\n\nNote: In the case of multiple simultaneous tumors,\nthe tumor with the highest T category will be\nclassified.\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor 2 cm or less in greatest dimension\nT2 Tumor more than 2 cm but not more\n than 5 cm in greatest dimension\nT3 Tumor more than 5 cm in greatest dimension\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\nT3 Tumor with invasion of maxilla, orbit, or temporal bone\nT4 Tumor with invasion of skeleton (axial or appendicular) or perineural\n invasion of skull base\nT88 NA\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Tis Carcinoma in situ\nT1 Tumor 2 cm or less in greatest dimension with less than two high risk\n features\nT2 Tumor greater than 2 cm in greatest dimension or\n Tumor any size with two or more high risk features\n\n
\nRegional Lymph Nodes (N)\n bilateral or contralateral lymph nodes, none more than 6 cm in\n greatest dimension\nN2a Metastasis in a single ipsilateral lymph node, more than 3 cm but not\n more than 6 cm in greatest dimension\nN2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm\n in greatest dimension\nN2c Metastasis in bilateral or contralateral lymph nodes, none more than\n 6 cm in greatest dimension\nN3 Metastasis in a lymph node, more than 6 cm in greatest dimension\nN88 NA\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single ipsilateral lymph node, 3 cm or less in\n greatest dimension\nN2 Metastasis in a single ipsilateral lymph node, more than 3 cm but not\n more than 6 cm in greatest dimension; or in multiple ipsilateral\n lymph nodes, none more than 6 cm in greatest dimension; or in\n\n
\nPrimary Tumor (T)\n margin, more than 5 mm but not more\n than 10 mm in greatest dimension\nT3 Tumor involves full eyelid thickness or, at\n the eyelid margin, more than 10 mm in\n greatest dimension\nT4 Tumor invades adjacent structures, which include\n bulbar conjunctiva, sclera and globe, soft tissues of\n the orbit, perineural space, bone and periosteum of\n the orbit, nasal cavity and paranasal sinuses, and\n central nervous system\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor of any size, not invading the tarsal\n plate or, at the eyelid margin, 5 mm or\n less in greatest dimension\nT2 Tumor invades tarsal plate or, at the eyelid\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\nT2b Tumor more than 10mm, but not more than 20 mm in greatest dimension\n Or, involves full thickness eyelid\nT3a Tumor more than 20 mm in greatest dimension\n Or, any tumor that invades adjacent ocular, or orbital structures\n Any T with perineural tumor invasion\nT3b Complete tumor resection requires enucleation, exenteration or bone \n resection\nT4 Tumor is not resectable due to extensive invasion of ocular, orbital,\n craniofacial structures or brain\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ\nT1 Tumor 5 mm or less in greatest dimension\n Not invading the tarsal plate or eyelid margin\nT2a Tumor more than 5 mm, but not more than 10 mm in greatest dimension\n Or, any tumor that invades the tarsal plate or eyelid margin\n\n
\nSchema Discriminator\n 8590-8671, 8930-8934, 8940-9110 coded in CSv1\n \n001 Male \n002 Female \n003 Other (hermaphrodite) \n004 Transsexual \n009 Unknown sex \n100 OBSOLETE DATA RETAINED V0200\n C48.1, C48.2, or C48.8, and histology in the ranges 8000-8576,\n\n
\nSchema Discriminator\n 8590-8671, 8930-8934, 8940-9110 coded in CSv1\n \n001 Male \n002 Female \n003 Other (hermaphrodite) \n004 Transsexual \n009 Unknown sex \n100 OBSOLETE DATA RETAINED V0200\n C48.1, C48.2, or C48.8, and histology in the ranges 8000-8576,\n\n
\nSchema Discriminator\n 8590-8671, 8930-8934, 8940-9110 coded in CSv1\n \n001 Male \n002 Female \n003 Other (hermaphrodite) \n004 Transsexual \n009 Unknown sex \n100 OBSOLETE DATA RETAINED V0200\n C48.1, C48.2, or C48.8, and histology in the ranges 8000-8576,\n\n
\nPrimary Tumor (T)\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1a Tumor 5 cm or less in greatest dimension - superficial tumor\nT1b Tumor 5 cm or less in greatest dimension - deep tumor\nT2a Tumor more than 5 cm in greatest dimension - superficial tumor\nT2b Tumor more than 5 cm in greatest dimension - deep tumor\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\nT1b Tumor more than 0.5 but not more than 1 cm in greatest dimension\nT1c Tumor more than 1 cm but not more than 2 cm in greatest dimension\nT2 Tumor more than 2 cm but not more than 5 cm in greatest dimension\nT3 Tumor more than 5 cm in greatest dimension\nT4 Tumor of any size with direct extension to (a) chest wall or (b) skin,\n only as described below.\nT4a Extension to chest wall\nT4b Edema (including peau d'orange) or ulceration of the skin of the\n breast or satellite skin nodules confined to the same breast\nT4c Both (T4a and T4b)\n \nT4d Inflammatory carcinoma\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ': Intraductal carcinoma, lobular carcinoma\n 'in situ', or Paget's disease of the nipple with no tumor\nT1 Tumor 2 cm or less in greatest dimension\nT1mi Microinvasion 0.1 cm or less in greatest dimension\nT1a Tumor more than 0.1 but not more than 0.5 cm in greatest dimension\n\n
\nRegional Lymph Nodes (N)\n structures\nN3 Metastasis to ipsilateral internal mammary\n lymph node(s)\n\nNX Regional lymph nodes cannot be assessed\n (e.g., previously removed)\nN0 No regional lymph node metastasis\nN1 Metastasis to movable ipsilateral axillary\n lymph node(s)\nN2 Metastasis to ipsilateral axillary lymph\n node(s) fixed to one another or to other\n\n
\nDistant Metastasis (M)\n\nMX Distant metastasis cannot be assessed\nM0 No distant metastasis\nM1 Distant metastasis (includes metastasis to\n ipsilateral supraclavicular lymph node[s])\n\n
\nRegional Lymph Nodes (N)\n to one another (matted) or to other structures\nN2b Metastasis only in clinically apparent ipsilateral internal mammary nodes\n and in the absence of clinically evident axillary lymph node metastasis\nN3 Metastasis in ipsilateral infraclavicular lymph node(s)\n with or without axillary lymph node involvement, or in clinically\n apparent ipsilateral internal mammary lymph node(s) and in the\n presence of clinically evident axillary lymph node metastasis;\n or metastasis in ipsilateral supraclavicular lymph node(s) with or\n without axillary or internal mammary lymph node involvement\nN3a Metastasis in ipsilateral infraclavicular lymph node(s)\n\nN3b Metastasis in ipsilateral internal mammary lymph node(s)\n and axillary lymph node(s)\nN3c Metastasis in ipsilateral supraclavicular lymph node(s)\nNX Regional lymph nodes cannot be assessed (e.g., previously removed)\nN0 No regional lymph node metastasis\nN1 Metastasis to movable ipsilateral axillary lymph node(s)\nN2 Metastasis to ipsilateral axillary lymph nodes fixed or matted,\n or in clinically apparent ipsilateral internal mammary nodes\n in the absence of clinically evident axillary lymph node metastasis\nN2a Metastasis to ipsilateral axillary lymph nodes fixed\n\n
\nPrimary Tumor (T)\n the underlying breast parenchyma. Carcinomas in the breast\n parenchyma associated with Paget's disease are categorized based\n on the size and characteristics of the parenchymal disease,\n although the presence of Paget's disease should still be noted\nT1 Tumor <= 20 mm in greatest dimension\nT1mi Tumor <= 1 mm in greatest dimension\nT1a Tumor >1 mm but <= 5 mm in greatest dimension\nT1b Tumor >5 mm but <= 10 mm in greatest dimension\nT1c Tumor >10 mm but <= 20 mm in greatest dimension\nT2 Tumor >20 mm but <= 50 mm in greatest dimension\n \nT3 Tumor >50 mm in greatest dimension\nT4 Tumor of any size with direct extension to the chest wall and/or to\n the skin (ulceration or skin nodules)\nT4a Extension to the chest wall, not including only pectoralis muscle\n adherence/invasion\nT4b Ulceration and/or ipsilateral satellite nodules and/or edema\n (including peau d'orange) of the skin which do not meet the\n criteria for inflammatory carcinoma\nT4c Both T4a and T4b\nT4d Inflammatory carcinoma\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ\n (DCIS) Ductal carcinoma in situ\n (LCIS) Lobular carcinoma in situ\n (Paget's) Paget's disease of the nipple is NOT associated with\n invasive carcinoma and/or carcinoma in situ (DCIS and/or LCIS) in\n\n
\nRegional Lymph Nodes (N)\nN0(i+) Malignant cells in regional lymph node(s) no greater than 0.2 mm \n (detected by H&E or IHC including ITC)\nN0(mol-) No regional lymph node metastases histologically, negative\n molecular findings (RT-PCR)\nN0(mol+) Positive molecular findings (RT-PCR), but no regional lymph node \n metastases detected by histology or IHC\nN1 Metastases to movable ipsilateral level I, II axillary lymph\n node(s)\n Micrometastases; or metastases in 1 to 3 axillary lymph nodes;\n and/or in internal mammary nodes with metastases detected by\n \n sentinel lymph node biopsy but not clinically detected\nN1mi Micrometastases (greater than 0.2 mm and/or more than 200 cells,\n but none greater than 2.0 mm)\nN1a Metastases in 1 to 3 axillary lymph nodes, at least one\n metastasis greater than 2.0 mm\nN1b Metastases in internal mammary nodes with micrometastases or\n macrometastases detected by sentinel lymph node biopsy but not\n clinically detected\nN1c Metastases in 1 to 3 axillary lymph nodes and in internal mammary\n lymph nodes with micrometastases or macrometastases detected by\nNX Regional lymph nodes cannot be assessed (e.g., previously\n sentinel lymph node biopsy but not clinically detected\nN2 Metastases in ipsilateral level I, II axillary lymph nodes that\n are clinically fixed or matted; or in clinically detected\n ipsilateral internal mammary nodes in the absence of clinically\n evident axillary lymph node metastases\n Metastases in 4 to 9 axillary lymph nodes; or in clinically\n detected internal mammary lymph nodes in the absence of\n axillary lymph node metastases\nN2a Metastases in ipsilateral axillary lymph nodes fixed to one\n another (matted) or to other structures\n removed)\n Metastases in 4 to 9 axillary lymph nodes (at least one tumor\n deposit greater than 2.0 mm)\nN2b Metastases only in clinically detected ipsilateral internal\n mammary nodes and in the absence of clinically evident axillary\n lymph node metastases\n Metastases in clinically detected internal mammary lymph nodes\n in the absence of axillary lymph node metastases\nN3 Metastases in ipsilateral infraclavicular (level III axillary)\n lymph node(s) with or without level I, II axillary lymph node\n involvement; or in clinically detected ipsilateral internal\n Regional lymph nodes cannot be assessed (e.g., previously\n mammary lymph node(s) with clinically evident level I, II\n axillary lymph node metastases; or metastases in ipsilateral \n supraclavicular lymph node(s) with or without axillary or\n internal mammary lymph node involvement\n Metastases in 10 or more axillary lymph nodes; or in\n infraclavicular (level III axillary) lymph nodes; or in\n clinically detected ipsilateral internal mammary lymph nodes in\n the presence of 1 or more positive level I, II axillary lymph\n nodes; or in more than 3 axillary lymph nodes and in internal\n mammary lymph nodes with micrometastases or macrometastases\n removed, or not removed for pathologic study)\n detected by sentinel lymph node biopsy but not clinically\n detected; or in ipsilateral supraclavicular lymph nodes\nN3a Metastases in ipsilateral infraclavicular lymph node(s) \n Metastases in 10 or more axillary lymph nodes (at least one tumor\n deposit greater than 2.0 mm); or metastases to the\n infraclavicular (level III axillary lymph) nodes\nN3b Metastases in ipsilateral internal mammary lymph node(s) and\n axillary lymph node(s)\n Metastases in clinically detected ipsilateral internal mammary\n lymph nodes in the presence of 1 or more positive axillary\nN0 No regional lymph node metastases\n lymph nodes; or in more than 3 axillary lymph nodes and in\n internal mammary lymph nodes with micrometastases or\n macrometastases detected by sentinel lymph node biopsy but not\n clinically detected\nN3c Metastases in ipsilateral supraclavicular lymph node(s)\n No regional lymph node metastasis identified histologically\nN0(i-) No regional lymph node metastases histologically, negative IHC\n\n
\nDistant Metastasis (M)\n radiographic means and/or histologically proven larger than 0.2\n mm\n \nM0 No clinical or radiographic evidence of distant metastases\nM0(i+) No clinical or radiographic evidence of distant metastases, but\n deposits of molecularly or microscopically detected tumor cells\n in circulating blood, bone marrow or other non-regional nodal\n tissue that are no larger than 0.2 mm in a patient without\n symptoms or signs of metastases\nM1 Distant detectable metastases as determined by classic clinical and\n\n
\nPrimary Tumor (T)\nT1b Tumor confined to the vulva or vulva and perineum, 2 cm or less in\n greatest dimension, and with stromal invasion greater than 1 mm*\nT2 Tumor confined to the vulva or vulva and perineum,\n more than 2 cm in greatest dimension\nT3 Tumor of any size with adjacent spread to the lower\n urethra and/or vagina or anus\nT4 Tumor invades any of the following: upper urethral mucosa,\n bladder mucosa, rectal mucosa, or is fixed to the pubic bone\n\n*Note: The depth of invasion is defined as the measurement of the tumor\n\nfrom the epithelial-stromal junction of the adjacent most superficial\ndermal papilla to the deepest point of invasion.\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ' (preinvasive carcinoma)\nT1 Tumor confined to the vulva or vulva and perineum,\n 2 cm or less in greatest dimension\nT1a Tumor confined to the vulva or vulva and perineum, 2 cm or less in\n greatest dimension, and with stromal invasion no greater than 1 mm*\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Unilateral regional lymph node metastasis\nN2 Bilateral regional lymph node metastasis\n\n
\nDistant Metastasis (M)\n\nMX Distant metastasis cannot be assessed\nM0 No distant metastasis\nM1 Distant metastasis (including pelvic\n lymph node metastasis)\n\n
\nPrimary Tumor (T)\nT2 Tumor of any size with extension to adjacent perineal structures\n (Lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal\n involvement)\nT3 Tumor of any size with extension to any of the following:\n upper/proximal 2/3 of urethra, upper/proximal 2/3 vagina, bladder\n mucosa, rectal mucosa, or fixed to pelvic bone\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ (preinvasive carcinoma)\nT1a Lesions <= 2 cm in size, confined to the vulva or perineum and with\n stromal invasion <= 1.0 mm\nT1b Lesions >2 cm in size or any size with stromal invasion >1.0 mm,\n confined to the vulva or perineum\n\n
\nRegional Lymph Nodes (N)\nN2b Two or more lymph node metastases 5 mm or greater\nN2c Lymph node metastasis with extracapsular spread\nN3 Fixed or ulcerated regional lymph node metastasis\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 One or two regional lymph node with the following features:\nN1a One or two lymph node metastasis each 5 mm or less\nN1b One lymph node metastases 5 mm or greater\nN2 Regional lymph node metastasis with the following features: \nN2a Three or more lymph node metastases each less than 5 mm\n\n
\nDistant Metastasis (M)\n \nM0 No distant metastasis\nM1 Distant metastasis (including pelvic lymph node metastasis)\n\n
\nPrimary Tumor (T)\nT3 III Tumor extends to pelvic wall\nT4 IVA Tumor invades mucosa of the bladder\n or rectum and/or extends beyond the\n true pelvis (bullous edema is not\n sufficient evidence to classify a\n tumor as T4)\n\n*Pelvic wall is defined as muscle, fascia, neurovascular\n structures, or skeletal portions of the bony pelvis.\n\nTNM FIGO\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis 0 Carcinoma 'in situ'\nT1 I Tumor confined to vagina\nT2 II Tumor invades paravaginal tissues\n but not to pelvic wall\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Pelvic or inguinal lymph node metastasis\n\n
\nPrimary Tumor (T)\n and 7.0 mm or less in horizontal spread\nT1a2 IA2 Measured stromal invasion more than 3.0 mm and not more\n than 5.0 mm with a horizontal spread 7.0 mm or less\nT1b IB Clinically visible lesion confined to the cervix or\n microscopic lesion greater than T1a2/IA2\nT1b1 IB1 Clinically visible lesion 4.0 cm or less in greatest dimension\nT1b2 IB2 Clinically visible lesion more than 4.0 cm in greatest dimension\nT2 II Cervical carcinoma invades beyond uterus but not \n to pelvic wall or to the lower third of vagina\nT2a IIA Tumor without parametrial invasion\n\nT2b IIB Tumor with parametrial invasion\nT3 III Tumor extends to pelvic wall, and/or involves the lower third of the\n vagina, and/or causes hydronephrosis or nonfunctioning kidney\nT3a IIIA Tumor involves lower third of the vagina,\n no extension to pelvic wall\nT3b IIIB Tumor extends to pelvic wall, and/or causes\n hydronephrosis or nonfunctioning kidney\nT4 IVA Tumor invades mucosa of the bladder or rectum and/or\n extends beyond true pelvis\nTNM FIGO\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis 0 Carcinoma 'in situ'\nT1 I Cervical carcinoma confined to uterus\nT1a IA Invasive carcinoma diagnosed only by microscopy\nT1a1 IA1 Measured stromal invasion 3.0 mm or less in depth\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\n epithelium and a horizontal spread of 7.0 mm or less. Vascular\n space involvement, venous or lymphatic, does not affect\n classification\nT1a1 Measured stromal invasion 3.0 mm or less in depth and 7.0 mm or less\n in horizontal spread\nT1a2 Measured stromal invasion more than 3.0 mm and not more than 5.0 mm\n with a horizontal spread 7.0 mm or less\nT1b Clinically visible lesion confined to the cervix or microscopic\n lesion greater than T1a/IA2\nT1b1 Clinically visible lesion 4.0 cm or less in greatest dimension\n \nT1b2 Clinically visible lesion more than 4.0 cm in greatest dimension\nT2 Cervical carcinoma invades beyond uterus but not to pelvic wall or\n to lower third of vagina\nT2a Tumor without parametrial invasion\nT2a1 Clinically visible lesion 4.0 cm or less in greatest dimension\nT2a2 Clinically visible lesion more than 4.0 cm in greatest dimension\nT2b Tumor with parametrial invasion\nT3 Tumor extends to pelvic wall and/or involves lower third of vagina,\n and/or causes hydronephrosis or non-functioning kidney\nT3a Tumor involves lower third of vagina, no extension to pelvic wall\nTX Primary tumor cannot be assessed\nT3b Tumor extends to pelvic wall and/or causes hydronephrosis or \n non-functioning kidney\nT4 Tumor invades mucosa of bladder or rectum, and/or extends beyond\n true pelvis (bullous edema is not sufficient to classify a tumor as\n T4)\nT0 No evidence of primary tumor\nTis Carcinoma in situ (preinvasive carcinoma)\nT1 Cervical carcinoma confined to uterus (extension to corpus should be\n disregarded)\nT1a Invasive carcinoma diagnosed only by microscopy. Stromal invasion\n with a maximum depth of 5.0 mm measured from the base of the\n\n
\nDistant Metastasis (M)\n \nM0 No distant metastasis\nM1 Distant metastasis (including peritoneal spread, involvement of\n supraclavicular, mediastinal, or paraaortic lymph nodes, lung, liver,\n or bone)\n\n
\nPrimary Tumor (T) (Surgical-Pathologic findings)\nT2 Tumor invades cervix but does not extend beyond uterus\nT2a Tumor limited to the glandular epithelium of the endocervix\nT2b Invasion of the stromal connective tissue of the cervix\nT3 Local and/or regional spread as defined below\nT3a Tumor involves serosa and/or adnexa (direct extension or meta-\n stasis) and/or cancer cells in ascites or peritoneal washings\nT3b Vaginal involvement (direct extension or metastasis)\nT4 Tumor invades bladder mucosa and/or bowel mucosa (bullous edema\n is not sufficient to classify a tumor as T4)\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor confined to corpus uteri\nT1a Tumor limited to endometrium\nT1b Tumor invades less than one-half of the myometrium\nT1c Tumor invades one-half or more of the myometrium\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\nT2 Tumor invades stromal connective tissue of the cervix but does not\n extend beyond uterus\nT3a Tumor involves serosa and/or adnexa (direct extension or metastasis)\nT3b Vaginal involvement (direct extension or metastasis) or parametrial\n involvement\nT4 Tumor invades bladder mucosa and/or bowel mucosa (bullous edema is\n not sufficient to classify a tumor as T4)\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ (preinvasive carcinoma)\nT1 Tumor confined to corpus uteri\nT1a Tumor limited to endometrium or invades less than one-half of the\n myometrium\nT1b Tumor invades one-half or more of the myometrium\n\n
\nRegional Lymph Nodes (N)\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis to pelvic lymph nodes\nN2 Regional lymph node metastasis to para-aortic lymph nodes, with or\n without positive pelvic lymph nodes\n\n
\nDistant Metastasis (M)\n \nM0 No distant metastasis\nM1 Distant metastasis (includes metastasis to inguinal lymph nodes \n intraperitoneal disease, or lung, liver, or bone. It excludes\n metastasis to para-aortic lymph nodes, vagina, pelvic serosa, or\n adnexa)\n\n
\nPrimary Tumor (T)\n following: capsule ruptured, tumor on ovarian surface,\n malignant cells in ascites or peritoneal washings\nT2 Tumor involves one or both ovaries with pelvic extension\nT2a Extension and/or implants on uterus and/or tube(s)\nT2b Extension to other pelvic tissues\nT2c Pelvic extension (2a or 2b) with malignant cells in ascites or peritoneal\n washings\nT3 Tumor involves one or both ovaries with microscopically\n confirmed peritoneal metastasis outside the pelvis\n and/or regional lymph node metastasis\n\nT3a Microscopic peritoneal metastasis beyond pelvis\nT3b Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest\n dimension\nT3c Peritoneal metastasis beyond pelvis more than 2 cm in\n greatest dimension and/or regional lymph node metastasis\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor limited to ovaries (one or both)\nT1a Tumor limited to one ovary; capsule intact, no tumor on ovarian surface\nT1b Tumor limited to both ovaries; capsules intact, no tumor on ovarian\n surface\nT1c Tumor limited to one or both ovaries with any of the\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\n the serosal surface; no ascites\nT1c Tumor limited to one or both tubes with extension\n onto or through the tubal serosa, or with\n malignant cells in ascites or peritoneal washings\nT2 Tumor involves one or both fallopian tubes with pelvic extension\nT2a Extension and/or metastasis to the uterus and/or ovaries\nT2b Extension to other pelvic structures\nT2c Pelvic extension with malignant cells\n in ascites or peritoneal washings\nT3 Tumor involves one or both fallopian tubes, with peritoneal implants\n\n outside the pelvis and/or positive regional lymph nodes\nT3a Microscopic peritoneal metastasis outside the pelvis\nT3b Macroscopic peritoneal metastasis outside the pelvis\n 2 cm or less in greatest dimension\nT3c Peritoneal metastasis more than 2 cm in diameter and/or positive\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ' (limited to tubal mucosa)\nT1 Tumor limited to the fallopian tube(s)\nT1a Tumor limited to one tube, without pentrating\n the serosal surface; no ascites\nT1b Tumor limited to both tubes, without penetrating\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Disease limited to uterus\nT2 Disease outside of uterus but is limited to\n genital structures (ovary,tube, vagina,\n broad ligaments)\n\n
\nPrimary Tumor (T)\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor confined to uterus\nT2 Tumor extends to other genital structures\n (ovary,tube, vagina, broad ligaments)\n by metastasis or direct extension\n\n
\nDistant Metastasis (M)\n \nM0 No distant metastasis\nM1a Lung metastasis\nM1b All other metastasis\n\n
\nPrimary Tumor (T)\nT4 Tumor invades other adjacent structures\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nTa Noninvasive verrucous carcinoma\nT1 Tumor invades subepithelial connective tissue\nT2 Tumor invades corpus spongiosum or cavernosum\nT3 Tumor invades urethra or prostate\n\n
\nRegional Lymph Nodes (N)\n lymph node(s) unilateral or bilateral\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single superficial,\n inguinal lymph node\nN2 Metastasis in multiple or bilateral\n superficial, inguinal lymph node\nN3 Metastasis in deep inguinal or pelvic\n\n
\nPrimary Tumor (T)\n differentiated\nT2 Tumor invades corpus spongiosum or cavernosum\nT3 Tumor invades urethra\nT4 Tumor invades other adjacent structures\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma in situ\nTa Noninvasive verrucous carcinoma\nT1a Tumor invades subepithelial connective tissue without lymph vascular \n invasion and is not poorly differentiated (i.e., grade 3-4)\nT1b Tumor invades subepithelial connective tissue with LVI or is poorly\n\n
\nPrimary Tumor, Clinical (T)\nT2a Tumor involves one lobe\nT2b Tumor involves both lobes\nT3 Tumor extends through the prostate capsule**\nT3a Extracapsular extension (unilateral or bilateral)\nT3b Tumor invades seminal vesicle(s)\nT4 Tumor is fixed or invades adjacent structures other than seminal vesicles:\n bladder neck, external sphincter, rectum, levator muscles, and/or pelvic\n wall\n\n*Note: Tumor found in one or both lobes by needle biopsy, but not palpable or\n\nreliably visible by imaging, is classfied as T1c.\n**Note: Invasion into the prostatic apex or into (but not beyond) the\nprostatic capsule is not classified as T3, but as T2.\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Clinically inapparent tumor not palpable nor visible by imaging\nT1a Tumor incidental histologic finding in 5% or less of tissue resected\nT1b Tumor incidental histologic finding in more than 5% of tissue resected\nT1c Tumor identified by needle biopsy (e.g., because of elevated PSA)\nT2 Tumor confined within prostate*\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in regional lymph node or nodes\n\n
\nDistant Metastasis (M)\n\nMX Distant metastasis cannot be assessed\nM0 No distant metastasis\nM1 Distant metastasis\nM1a Nonregional lymph node(s)\nM1b Bone(s)\nM1c Other site(s)\n\n
\nPrimary Tumor, Clinical (T)\nT2a Tumor involves one-half of one lobe or less\nT2b Tumor involves more than one-half of one lobe but not both lobes\nT2c Tumor involves both lobes\nT3 Tumor extends through the prostate capsule\nT3a Extracapsular extension (unilateral or bilateral)\nT3b Tumor invades seminal vesicle(s)\nT4 Tumor is fixed or invades adjacent structures other than seminal\n vesicles: bladder neck, external sphincter, rectum, levator muscles,\n and/or pelvic wall\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Clinically inapparent tumor not palpable nor visible by imaging\nT1a Tumor incidental histologic finding in 5% or less of tissue resected\nT1b Tumor incidental histologic finding in more than 5% of tissue resected\nT1c Tumor identified by needle biopsy (e.g., because of elevated PSA)\nT2 Tumor confined within prostate\n\n
\nRegional Lymph Nodes, Clinical (N)\n\nNX Regional lymph nodes were not assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in regional lymph node(s)\n\n
\nPrimary Tumor (pT)\nTis Intratubular germ cell neoplasia (carcinoma 'in situ')\nT1 Tumor limited to the testis and epididymis without\n vascular/lymphatic invasion; tumor may invade into\n the tunica albuginea but not the tunica vaginalis \nT2 Tumor limited to the testis and epididymis with\n vascular/lymphatic invasion, or tumor extending through the\n tunica albuginea with involvement of the tunica vaginalis \nT3 Tumor invades the spermatic cord with or without\n vascular/lymphatic invasion\nT4 Tumor invades the scrotum with or without vascular/lymphatic invasion\n\nThe extent of primary tumor is classfied\nafter radical orchiectomy.\n\nTX Primary tumor cannot be assessed (if no radical\n orchiectomy has been performed, Tx is used)\nT0 No evidence of primary tumor (e.g. histologic\n scar in testis)\n\n
\nRegional Lymph Nodes (N)\n or multiple lymph nodes, any one mass greater\n than 2 cm but not more than 5 cm in greatest\n dimension\nN3 Metastasis with a lymph node mass more than 5\n cm in greatest dimension\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis with a lymph node mass 2 cm or less\n in greatest dimension; or multiple lymph nodes,\n none more than 2 cm in greatest dimension\nN2 Metastasis with a lymph node mass more than 2\n cm but not more than 5 cm in greatest dimension;\n\n
\nDistant Metastasis (M)\n\nMx Distant metastasis cannot be assessed\nM0 No distant metastasis\nM1 Distant metastasis\nM1a Nonregional nodal or pulmonary metastasis\nM1b Distant metastasis other than to nonregional\n lymph nodes and lungs\n\n
\nPrimary Tumor (T)\n adrenal gland or perinephric tissues, but\n not beyond Gerota's fascia\nT3a Tumor invades the adrenal gland or perinephric\n tissues but not beyond Gerota's fascia\nT3b Tumor grossly extends into the renal vein(s) \n or vena cava below the diaphragm\nT3c Tumor grossly extends into the renal vein(s) \n or vena cava above the diaphragm\nT4 Tumor invades beyond Gerota's fascia\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor 7 cm or less in greatest dimension\n limited to the kidney\nT2 Tumor more than 7 cm in greatest dimension\n limited to the kidney\nT3 Tumor extends into major veins or invades the\n\n
\nRegional Lymph Nodes (N)*\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastases\nN1 Metastasis in a single regional lymph node\nN2 Metastasis in more than one regional lymph node\n\n*Note: Laterality does not affect the N classification.\n\n
\nPrimary Tumor (T)\n limited to the kidney\nT2 Tumor more than 7 cm in greatest dimension,\n limited to the kidney\nT3 Tumor extends into major veins or invades the\n adrenal gland or perinephric tissues, but\n not beyond Gerota's fascia\nT3a Tumor invades the adrenal gland or perirenal\n and/or renal sinus fat but not beyond Gerota's fascia\nT3b Tumor grossly extends into the renal vein or its segmental\n (muscle-containing) branches, or vena cava below the diaphragm\n\nT3c Tumor grossly extends into the vena cava above diaphragm\n or invades the wall of the vena cava\nT4 Tumor invades beyond Gerota's fascia\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor 7 cm or less in greatest dimension,\n limited to the kidney\nT1a Tumor 4 cm or less in greatest dimension,\n limited to the kidney\nT1b Tumor more than 4 cm but not more than 7 cm in greatest dimension,\n\n
\nPrimary Tumor (T)\nT2a Tumor more than 7 cm but less than or equal to 10 cm in greatest \n dimension, limited to the kidney\nT2b Tumor more than 10 cm, limited to the kidney\nT3 Tumor extends into major veins or perinephric tissues but not into\n the ipsilateral adrenal gland and not beyond Gerota's fascia\nT3a Tumor grossly extends into the renal vein or its segmental (muscle \n containing) branches, or tumor invades perirenal and/or renal sinus\n fat but not beyond Gerota's fascia\nT3b Tumor grossly extends into the vena cava below the diaphragm\nT3c Tumor grossly extends into the vena cava above the diaphragm or\n \n invades the wall of the vena cava\nT4 Tumor invades beyond Gerota's fascia (including contiguous extension\n into the ipsilateral adrenal gland)\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor 7 cm or less in greatest dimension, limited to the kidney\nT1a Tumor 4 cm or less in greatest dimension, limited to the kidney\nT1b Tumor more than 4 cm but not more than 7 cm in greatest dimension\n limited to the kidney\nT2 Tumor more than 7 cm in greatest dimension, limited to the kidney\n\n
\nRegional Lymph Nodes (N)\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\n peripelvic fat or the renal parenchyma\nT4 Tumor invades adjacent organs, or through the\n kidney into the perinephric fat\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTa Papillary noninvasive carcinoma\nTis Carcinoma 'in situ'\nT1 Tumor invades subepithelial connective tissue\nT2 Tumor invades the muscularis\nT3 Tumor invades beyond the muscularis into\n\n
\nRegional Lymph Nodes (N)*\n more than 5 cm in greatest dimension\nN3 Metastasis in a lymph node more than\n 5 cm in greatest dimension\n\n*Note: Laterality does not affect the N classification.\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single lymph node,\n 2 cm or less in greatest dimension\nN2 Metastasis in a single lymph node, more than\n 2 cm but not more than 5 cm in greatest\n dimension; or multiple lymph nodes, none\n\n
\nPrimary Tumor (T)\n periureteric fat\nT4 Tumor invades adjacent organs, or through the\n kidney into the perinephric fat\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTa Papillary noninvasive carcinoma\nTis Carcinoma 'in situ'\nT1 Tumor invades subepithelial connective tissue\nT2 Tumor invades the muscularis\nT3 Tumor invades beyond the muscularis into\n\n
\nRegional Lymph Nodes (N)*\n more than 5 cm in greatest dimension\nN3 Metastasis in a lymph node more than\n 5 cm in greatest dimension\n\n*Note: Laterality does not affect the N classification.\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single lymph node,\n 2 cm or less in greatest dimension\nN2 Metastasis in a single lymph node, more than\n 2 cm but not more than 5 cm in greatest\n dimension; or multiple lymph nodes, none\n\n
\nPrimary Tumor (T)\nT2b Tumor invades deep muscle (outer half)\nT3 Tumor invades perivesical tissue\nT3a microscopically\nT3b macrospocically (extravesical mass)\nT4 Tumor invades any of the following:\n prostate, uterus, vagina, pelvic wall,\n adominal wall\nT4a Tumor invades prostate, uterus, vagina\nT4b Tumor invades pelvic wall, abdominal wall\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTa Noninvasive papillary carcinoma\nTis Carcinoma 'in situ': "flat tumor"\nT1 Tumor invades subepithelial connective tissue\nT2 Tumor invades muscle\nT2a Tumor invades superficial muscle (inner half)\n\n
\nRegional Lymph Nodes (N)\nN2 Metastasis in a single lymph node, more than\n 2 cm but not more than 5 cm in greatest\n dimension; or multiple lymph nodes, none\n more than 5 cm in greatest dimension\nN3 Metastasis in a lymph node more than\n 5 cm in greatest dimension\n\nRegional lymph nodes are those within the true\npelvis; all others are distant lymph nodes.\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single lymph node,\n 2 cm or less in greatest dimension\n\n
\nRegional Lymph Nodes (N)\nN3 Lymph node metastasis to the common iliac lymph nodes\n \nNX Lymph nodes cannot be assessed\nN0 No lymph node metastasis\nN1 Single regional lymph node metastasis in the true pelvis (hypogastric,\n obturator, external iliac or presacral lymph node)\nN2 Multiple regional lymph node metastasis in the true pelvis\n (hypogastric, obturator, external iliac or presacral lymph node\n metastasis)\n\n
\nPrimary Tumor (T) (male and female)\n spongiosum, prostate, periurethral muscle\nT3 Tumor invades any of the following: corpus\n cavernosum, beyond prostatic capsule, \n anterior vagina, bladder neck\nT4 Tumor invades other adjacent organs\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTa Noninvasive papillary, polypoid, or verrucous\n carcinoma\nTis Carcinoma 'in situ'\nT1 Tumor invades subepithelial connective tissue\nT2 Tumor invades any of the following: corpus\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in a single lymph node,\n 2 cm or less in greatest dimension\nN2 Metastasis in a single lymph node more\n than 2 cm in greatest dimension, or in\n multiple nodes\n\n
\nPrimary Tumor (T)\n excluding the orbit\nT4 Tumor invades the orbit\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor 5 mm or less in greatest dimension\nT2 Tumor more than 5 mm in greatest dimension,\n without invasion of adjacent structures\nT3 Tumor invades adjacent structures,\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\n excluding the orbit\nT4 Tumor invades the orbit with or without further\n extension\nT4a Tumor invades orbital soft tissues, without bone\n invasion\nT4b Tumor invades bone\nT4c Tumor invades adjacent paranasal sinuses\nT4d Tumor invades brain\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nTis Carcinoma 'in situ'\nT1 Tumor 5 mm or less in greatest dimension\nT2 Tumor more than 5 mm in greatest dimension,\n without invasion of adjacent structures\nT3 Tumor invades adjacent structures,\n\n
\nPrimary Tumor (T)\nT3a Tumor(s) involve(s) more than 50% of the retina\n and/or tumor cells in the vitreous\nT3b Tumor(s) involve(s) optic disc\nT3c Tumor(s) involve(s) anterior chamber and/or uvea\nT4 Tumor with extra-ocular invasion\nT4a Tumor invades retrobulbar optic nerve\nT4b Extra-ocular extension other than invasion of optic nerve\n\nNote: The following suffixes may be added to the appropriate T categories:\n"m" indicates multiple tumors (e.g. T2m2); "f" indicates cases with a known\n\nfamily history; and "d" indicates diffuse retinal involvement without the\nformation of discrete masses.\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor(s) limited to 25% or less of the retina\nT2 Tumor(s) involve(s) more than 25% but not more\n than 50% of the retina\nT3 Tumor(s) involve(s) more than 50% of the retina and/or\n invade(s) beyond the retina but remain(s) intra-ocular\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\n nerve or fovea\nT1b All other eyes in which the tumor(s) are confined to the retina\n regardless of location or size (up to half the volume of the eye).\n No vitreous seeding. No retinal detachment or subretinal fluid >5 mm\n from the base of the tumor.\nT2 Tumor with contiguous spread to adjacent tissues or spaces (vitreous or\n subretinal space).\nT2a Minimal spread to vitreous and/or subretinal space\nT2b Massive spread to vitreous and/or subretinal space\nT2c Unsalvageable intraocular disease\n\nT3 Invasion of optic nerve and/or optic coats\nT4 Extraocular tumor\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor confined to the retina (no vitreous seeding or significant retinal\n detachment). No retinal detachment or subretinal fluid >5 mm from the\n base of the tumor\nT1a Any eye in which the largest tumor is less than or equal to 3 mm in\n height and no tumor is located closer than 1 DD (1.5 mm) to the optic\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node involvement\nN1 Regional lymph node involvement (preauricular,\n submandibular, or cervical)\n\n
\nDistant Metastasis (M)\n\nMX Distant metastasis cannot be assessed\nM0 No distant metastasis\nM1 Distant metastasis\n\n
\nPrimary Tumor (T)\n located closer than 1.5 mm to the optic nerve or fovea. No retinal\n detachment or subretinal fluid beyond 5 mm from the base of the\n tumor\nT1c At least one tumor is greater than 3 mm in largest dimension or\n located closer than 1.5 mm to the optic nerve or fovea. With retinal\n detachment or subretinal fluid beyond 5 mm from the base of the\n tumor\nT2 Tumors no more than 2/3 the volume of the eye with vitreous or\n subretinal seeding. Can have retinal detachment.\nT2a Focal vitreous and/or subretinal seeding of fine aggregates of tumor \n \n cells is present, but no large clumps or "snowballs of tumor cells\nT2b Massive vitreous and/or subretinal seeding is present, defined as\n diffuse clumps or "snowballs of tumor cells\nT3 Severe intraocular disease\nT3a Tumor fills more than 2/3 of the eye.\nT3b One or more complications present, which may include tumor-associated\n neovascular or angle closure glaucoma, tumor extension into the\n anterior segment, hyphema, vitreous hemorrhage, or orbital\n cellulitis\nT4 Extraocular disease detected by imaging studies\nTX Primary tumor cannot be assessed\nT4a Invasion of optic nerve\nT4b Invasion into the orbit.\nT4c Intracranial extension not past chiasm\nT4d Intracranial extension past chiasm\nT0 No evidence of primary tumor\nT1 Tumors no more than 2/3 the volume of the eye with no vitreous or \n subretinal seeding\nT1a No tumor in either eye is greater than 3 mm in largest dimension or \n located closer than 1.5 mm to the optic nerve or fovea\nT1b At least one tumor is greater than 3 mm in largest dimension or\n\n
\nRegional Lymph Nodes (N)\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node involvement\nN1 Regional lymph node involvement (preauricular, cervical,\n submandibular)\nN2 Distant lymph node involvement\n\n
\nDistant Metastasis (M)\n \nM0 No distant metastasis\nM1 Systemic metastasis\nM1a Single lesion to sites other than CNS\nM1b Multiple lesions to sites other than CNS\nM1c Prechiasmatic CNS lesion(s)\nM1d Postchiasmatic CNS lesion(s)\nM1e Leptomeningeal and/or CSF involvement\n\n
\nPrimary Tumor (T)\n an elevation more than 3 mm but not more than 5 mm\nT3* Tumor more than 15 mm in greatest dimension or\n with an elevation more than 5 mm\nT4 Tumor with extraocular extension\n\nNote: When dimension and elevation show a difference in classification, the\nhighest category should be used for classification.\n*Note: In clinical practice the tumor base may be estimated in optic disc\ndiameters (dd) (average: 1 dd = 1.5 mm). The elevation may be estimated in\ndiopters (average: 3 diopters = 1 mm). Other techniques used, such as\n\nultrasonography and computerized stereometry, may provide a more accurate\nmeasurement.\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1* Tumor 10 mm or less in greatest dimension with an elevation 3 mm or less\nT1a Tumor 7 mm or less in greatest dimension with an elevation 2 mm or less\nT1b Tumor more than 7 mm but not more than 10 mm in greatest dimension with\n an elevation more than 2 mm but not more than 3 mm\nT2* Tumor more than 10 mm but not more than 15 mm in greatest dimension with\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\nT1b Tumor 10 mm or less in greatest dimension and 2.5 mm or less in greatest\n height (thickness) with microscopic extraocular extension\nT1c Tumor 10 mm or less in greatest dimension and 2.5 mm or less in greatest\n height (thickness) with macroscopic extraocular extension\nT2 Tumor greater than 10 mm but not more than 16 mm in greatest basal\n diameter and between 2.5 and 10 mm in maximum height (thickness)\nT2a Tumor 10 mm to 16 mm in greatest basal diameter and between 2.5 and 10 mm\n in maximum height (thickness) without microscopic extraocular extension\nT2b Tumor 10 mm to 16 mm in greatest basal diameter and between 2.5 and 10 mm\n in maximum height (thickness) with microscopic extraocular extension\nChoroid\nT2c Tumor 10 mm to 16 mm in greatest basal diameter and between 2.5 and 10 mm\n in maximum height (thickness) with macroscopic extraocular extension\nT3 Tumor more than 16 mm in greatest diameter and/or greater than 10 mm in\n maximum height (thickness) without extraocular extension\nT4 Tumor more than 16 mm in greatest diameter and/or greater than 10 mm in\n maximum height (thickness) with extraocular extension\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor 10 mm or less in greatest dimension and 2.5 mm or less in greatest\n height (thickness)\nT1a Tumor 10 mm or less in greatest dimension and 2.5 mm or less in greatest\n height (thickness) without microscopic extraocular extension\n\n
\nPrimary Tumor (T)\n angle, ciliary body, and/or choroid\nT4 Tumor with extraocular extension\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor limited to iris\nT2 Tumor involves one quadrant or less, with\n invasion into the anterior chamber angle\nT3 Tumor involves more than one quadrant,\n with invasion into the anterior chamber\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\n in size\nT1c Tumor limited to the iris with melanomalytic\n glaucoma\nT2 Tumor confluent with or extending into the ciliary\n body and/or choroid\nT2a Tumor confluent with or extending into the ciliary\n body and/or choroid with melanomalytic glaucoma\nT3 Tumor confluent with or extending into the ciliary\n body and/or choroid with scleral extension\nT3a Tumor confluent with or extending into the ciliary\nIris\n body with scleral extension and melanomalytic glaucoma\nT4 Tumor with extraocular extension\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor limited to the iris\nT1a Tumor limited to the iris not more than 3 clock\n hours in size\nT1b Tumor limited to the iris more than 3 clock hours\n\n
\nPrimary Tumor (T)\nT2 Tumor confluent with or extending into the ciliary body, choroid or\n both\nT2a Tumor confluent with or extending into the ciliary body, choroid or\n both, with secondary glaucoma\nT3 Tumor confluent with or extending into the ciliary body, choroid or\n both, with scleral extension\nT3a Tumor confluent with or extending into the ciliary body, choroid or\n both, with scleral extension and secondary glaucoma\nT4 Tumor with extrascleral extension\nT4a Tumor with extrascleral extension less than or equal to 5 mm in\n \n diameter\nT4b Tumor with extrascleral extension more than 5 mm in diameter\nIris\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor limited to the iris\nT1a Tumor limited to the iris not more than 3 clock hours in size\nT1b Tumor limited to the iris more than 3 clock hours in size\nT1c Tumor limited to the iris with secondary glaucoma\n\n
\nDistant Metastasis (M)\n \nM0 No distant metastasis\nM1 Distant metastasis\nM1a Largest diameter of the largest metastasis <=3 cm\nM1b Largest diameter of the largest metastasis 3.1-8.0 cm\nM1c Largest diameter of the largest metastasis 8.1 cm or more\n\n
\nSchema Discriminator: Melanoma Ciliary Body/Melanoma Iris\n100 OBSOLETE DATA RETAINED V0200\n C69.4 - originally coded in CSv1 \n \n010 Ciliary Body\n Crystalline lens\n Sclera\n Uveal tract\n Intraocular\n Eyeball \n020 Iris \n\n
\nPrimary Tumor (T)\n than 5 cm in greatest dimension\nT3a Tumor limited to the lacrimal gland\nT3b Tumor invades the periosteum of the\n fossa of the lacrimal gland\nT4 Tumor more than 5 cm in greatest dimension\nT4a Tumor invades the orbital soft tissues, optic\n nerve, or globe without bone invasion\nT4b Tumor invades the orbital soft tissues, optic\n nerve, or globe with bone invasion\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor 2.5 cm or less in greatest dimension\n limited to the lacrimal gland\nT2 Tumor 2.5 cm or less in greatest dimension invading\n the periosteum of the fossa of the lacrimal gland \nT3 Tumor more than 2.5 cm but not more\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\nT3a Tumor not more than 5 cm invades the periosteum\n of the lacrimal gland fossa\nT3b Tumor more than 5 cm in greatest dimension with\n periosteal invasion\nT4 Tumor invades the orbital soft tissues, optic\n nerve, or globe with or without bone invasion;\n tumor extends beyond the orbit to adjacent\n structures, including brain\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor 2.5 cm or less in greatest dimension,\n limited to the lacrimal gland\nT2 Tumor more than 2.5 cm but not more than 5 cm in greatest dimension,\n limited to the lacrimal gland \nT3 Tumor invades the periosteum\n\n
\nPrimary Tumor (T)\nT4a Tumor invades periosteum\nT4b Tumor invades orbital bone\nT4c Tumor invades adjacent structures (brain, sinus, pterygoid fossa,\n temporal fossa)\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor 2 cm or less in greatest dimension, with or without\n extraglandular extension into the orbital soft tissue\nT2 Tumor more than 2 cm but not more than 4 cm in greatest dimension\nT3 Tumor more than 4 cm in greatest dimension\nT4 Tumor invades periosteum or orbital bone or adjacent structures\n\n
\nSchema Discriminator: Lacrimal Gland/Lacrimal Sac\n \n015 Lacrimal gland\n Lacrimal, NOS\n \nOBSOLETE DATA CONVERTED V0203\nSee code 025\n020 Lacrimal sac \n \n025 Lacrimal sac\n Lacrimal duct, NOS\n \n Nasal lacrimal duct\n Nasolacrimal duct\n \n100 OBSOLETE DATA RETAINED V0200\n C69.5- originally coded in CSv1 and\n case diagnosed before 1/1/2010\nOBSOLETE DATA REVIEWED AND CHANGED V0203\nSee codes 015,025\n010 Lacrimal gland\n Lacrimal duct, NOS\n Nasal lacrimal duct\n Nasolacrimal duct\n Lacrimal, NOS\n\n
\nPrimary Tumor (T)\nT4 Tumor invasion of globe or periorbital structure,\n such as eyelids, temporal fossa, nasal cavity and\n paranasal sinuses, and/or central nervous system\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor 15 mm or less in greatest dimension\nT2 Tumor more than 15 mm in greatest dimension\n without invasion of globe or bony wall\nT3 Tumor of any size with invasion of orbital tissues\n and/or bony walls\n\n
\nRegional Lymph Nodes (N)\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\n limited to the thyroid\nT2 Tumor more than 1 cm but not more than 4 cm\n in greatest dimension limited to the thyroid\nT3 Tumor more than 4 cm in greatest dimension\n limited to the thyroid\nT4 Tumor of any size extending beyond the thyroid\n capsule\n \nNote: All categories may be subdivided:\n(a) solitary tumor, (b) multifocal tumor\n(the largest determines the classification)\n\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor 1 cm or less in greatest dimension\n\n
\nRegional Lymph Nodes (N)\nN1b Metastasis in bilateral, midline, or contralateral\n cervical or mediastinal lymph node(s)\n\nRegional lymph nodes are the cervical\nand upper mediastinal lymph nodes.\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\nN1a Metastasis in ipsilateral cervical lymph node(s)\n\n
\nPrimary Tumor (T)\n extrathyroid extension (eg, extension to\n sternothyroid muscle or perithyroid soft tissues)\nT4a Tumor of any size extending beyond the thyroid capsule\n to invade subcutaneous soft tissues, larynx, trachea,\n esophagus, or recurrent laryngeal nerve\nT4b Tumor invades prevertebral fascia or\n encases carotid artery or mediastinal vessels\n\nAll anaplastic carcinomas are considered T4 tumors.\n\n \nT4a Intrathyroidal anaplastic carcinoma - surgically resectable\nT4b Extrathyroidal anaplastic carcinoma - surgically unresectable \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor 2 cm or less in greatest dimension limited to the thyroid\nT2 Tumor more than 2 cm, but not more than 4\n cm, in greatest dimension limited to the thyroid\nT3 Tumor more than 4 cm in greatest dimension\n limited to the thyroid or any tumor with minimal\n\n
\nRegional Lymph Nodes (N)\nN1a Metastasis to Level VI (pretracheal,\n paratracheal, and prelaryngeal/Delphian lymph\n nodes)\nN1b Metastasis to unilateral, bilateral, or\n contralateral cervical or superior mediastinal\n lymph nodes\n\nRegional lymph nodes are the central\ncompartment, lateral cervical, and upper\nmediastinal lymph nodes.\n\nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\n\n
\nPrimary Tumor (T)\n limited to the thyroid\nT3 Tumor more than 4 cm in greatest dimension limited to the thyroid, or\n any tumor with minimal extrathyroid extension (e.g., extension to\n sternothyroid muscle or perithyroid soft tissues)\nT4a Moderately advanced disease.\n Tumor of any size extending beyond the thyroid capsule to invade\n subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent\n laryngeal nerve\n Intrathyroidal anaplastic carcinoma\nT4b Very advanced disease.\n \n Tumor invades prevertebral fascia or encases carotid artery or\n mediastinal vessels\n Anaplastic carcinoma with gross extrathyroid extension\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor 2 cm or less in greatest dimension limited to the thyroid\nT1a Tumor 1 cm or less, limited to the thyroid\nT1b Tumor more than 1 cm but not more than 2 cm in greatest dimension, \n limited to the thyroid\nT2 Tumor more than 2 cm but not more than 4 cm in greatest dimension, \n\n
\nRegional Lymph Nodes (N)\n mediastinal lymph nodes (Level VII)\n \nNX Regional lymph nodes cannot be assessed.\nN0 No regional lymph node metastasis\nN1 Regional lymph node metastasis\nN1a Metastasis to Level VI (pretracheal, paratracheal, and \n prelaryngeal/Delphian lymph nodes)\nN1b Metastasis to unilateral, bilateral, or contralateral cervical\n (Levels I, II, III, IV or V) or retropharyngeal or superior\n\n
\nPrimary Tumor (T)\n \nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor\nT1 Tumor 5 cm or less in greatest dimension, no extra-adrenal invasion\nT2 Tumor greater than 5 cm, no extra-adrenal invasion\nT3 Tumor of any size with local invasion, but not invading adjacent \n organs\nT4 Tumor of any size with invasion of adjacent organs\n\n
\nRegional Lymph Nodes (N)\n \nNX Regional lymph nodes cannot be assessed\nN0 No regional lymph node metastasis\nN1 Metastasis in regional lymph node(s)\n\n